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 Lyme disease (LD) is a bacterial illness caused by infection primarily with 
Borrelia burgdorferi, which is mainly transmitted by the bite of infected Ixodes scapularis 
ticks in the United States (U.S.). Annually, over 30,000 cases of this multi-system 
disease are reported to the Centers for Disease Control and Prevention, but recent 
studies have provided evidence that the true number of cases is estimated to be over 
300,000 each year, a substantial disease burden. Studies evaluating currently available 
prevention methods (e.g., repellent use, yard-based pesticides) have not demonstrated 
an effect on disease reduction. An LD vaccine was available 1998 – 2002 in the U.S. 
until it was voluntarily discontinued by the manufacturer due to low demand caused by 
several factors, despite it being both safe and effective. Since then, the number of LD 
cases reported annually has nearly doubled.  
New vaccine candidates are currently in development with estimated availability 
during 2022 – 2024. However, before any future LD vaccine can be recommended by 
the Advisory Committee on Immunization Practices (ACIP), current research gaps must 
be addressed. Comprehensive estimates of the cost of LD to the patient and society are 
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lacking; there is a dearth of research regarding public acceptance of a potential LD 
vaccine; and the economic benefit of a hypothetical vaccination strategy in the U.S. is 
unknown. 
Methods 
 To address the first gap regarding the cost of LD in the U.S., we conducted a 
prospective, cost of illness study to estimate the total costs incurred due to incident LD 
using a societal perspective (Chapter 3). Data were collected from participants and their 
providers to estimate medical costs, non-medical costs, and productivity losses 
attributable to LD in endemic states. Recruitment took place among physician-
diagnosed, reported LD cases in Connecticut, Maryland, Minnesota, and New York. 
Sample-weighted, descriptive statistics were conducted to estimate the out-of-pocket 
cost of LD per patient and the total societal cost of LD per patient, overall and by LD 
category (confirmed localized, confirmed disseminated, and probable disease). Linear 
regression analysis was used to evaluate associations between total societal cost per 
patient and the following independent variables of interest: LD disease category, age 
group, gender, and state. 
 To address the second gap regarding public acceptability of a potential LD 
vaccine, we conducted a cross-sectional, population-based survey of persons living in 
LD endemic states (Chapter 4). A web-based survey was administered to a random 
sample of Connecticut, Maryland, Minnesota, and New York residents June – July, 
2018. Sample-weighted, descriptive statistics were conducted to estimate the proportion 
willing to receive vaccination against LD. Multivariable, multinomial logistic regression 
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models were used to quantify the association of sociodemographic characteristics and 
LD vaccine attitudes with willingness to receive vaccination against LD.  
Lastly, to address the third gap regarding the economic benefit of a LD 
vaccination strategy in the U.S., we conducted a cost-benefit analysis to estimate the 
net cost of vaccination against Lyme disease (Chapter 5). A decision-analytic model 
was used to compare a vaccination strategy to no vaccination among a hypothetical 
cohort of 100,000 individuals living in high incidence areas over a three-year time 
horizon. Probabilities and costs for vaccine and clinical parameters were estimated from 
the literature as well as from primary research (chapters 3 and 4). Deterministic 
sensitivity analyses were conducted. Model outputs included cases averted, the total 
net cost of the vaccination strategy, cost per case averted, and net cost per vaccinee.  
Results 
 In the cost of illness study, patients had an average out-of-pocket cost of 
approximately $1,340 (median $270) and an average total cost of approximately $2,270 
(median $770) (2020 USD) for LD. In stratified analyses by disease category, those with 
confirmed disseminated and probable disease had approximately double or more the 
total cost per patient compared to those with confirmed localized disease. Having 
disseminated or probable disease, being aged 18 – 65 years, and having residence in 
MN had the greatest impact on the total cost of LD. The aggregate cost of diagnosed 
LD could be upwards of $800 million annually in the United States.  
 In the LD vaccine acceptability survey, we estimated that 64% of residents were 
willing to receive a LD vaccine, while 30% were uncertain and 7% were not willing. 
Those who were uncertain had higher odds of being parents, adults 45 – 65 years of 
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age, non-white, having less than a bachelor’s degree, or having concerns about the 
safety of a potential LD vaccine compared to those who were willing. Those who were 
unwilling also had higher odds of being non-white, having less than a bachelor’s degree, 
or having concerns about the safety of a potential LD vaccine, but they also would not 
be influenced by a positive recommendation from a HCP, had low confidence in 
vaccines in general, and had low perceived risk of contracting LD compared to those 
who were willing.  
 Lastly, from the cost-benefit analysis, we estimated that 2,160 cases would be 
averted during a three-year period for a 100,000-person cohort residing in an area with 
an LD incidence of 0.01. The net cost of the vaccination strategy was $12,510,475, 
which translates to a cost per case averted of $9,301 and a net cost per vaccinee of 
$156 over a three-year period. The net cost per vaccinee was most sensitive to 
changes in vaccine price and disease incidence, with a $0 net cost resulting from a 
vaccine price of $45 at an incidence of 0.01 or a vaccine price of $476 at an incidence 
of 0.08.  
Conclusions 
This research provides critical information for public health considerations for a 
potential LD vaccine in the U.S., including new information on the economic burden of 
LD, the acceptability of a potential LD vaccine by the public, and the net cost of a 
potential vaccination program. In the cost of illness study, we found that most LD 
patients have low costs, but some experience very high costs related to LD; further, the 
total economic burden of diagnosed LD in the U.S. could be upwards of $800 million 
annually, a significant societal cost. These findings emphasize the importance of 
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effective prevention and early diagnosis to reduce morbidity and associated costs. 
Results can be used in economic evaluations of current and future prevention methods, 
such as a vaccine.  
We also found that acceptance of a LD vaccine among potential consumers was 
high, with over 60% willing to receive vaccination, approximately 30% uncertain, and 
less than 10% unwilling. Effective communication by clinicians regarding safety and 
other vaccine parameters to those groups who are uncertain about LD vaccination (i.e., 
parents, adults 45 – 65 years of age, those who are non-white, and those with lower 
education) will be critical for increasing vaccine uptake and reducing LD incidence. 
Using these cost and vaccine acceptability results, we estimated that a 
vaccination program in areas with a high incidence of LD could generate a net cost of 
approximately $150 per vaccinee over three years of vaccine effectiveness. Many 
counties in endemic states have annual incidence greater than 0.01, and while the price 
of a potential vaccine is currently unknown, it is possible that an eventual vaccine could 
be cost saving. This analysis should be repeated when price and performance 
parameters for a LD vaccine are available.  
With currently available prevention measures failing to decrease LD incidence, 
new vaccine candidates have the potential to make a substantial impact on the 
morbidity and economic burden of LD in the U.S. The ACIP makes national 
recommendations for the use of licensed vaccines based on factors such as disease 
burden, public acceptance, public health impact, cost, vaccine supply, and other 
considerations beyond the safety and efficacy data used for FDA approval. The results 
from this research provide important, complementary information that may be 
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considered by the ACIP in making recommendations for a new LD vaccine, when 
available. Specifically, these results show the need for, potential public demand for, and 
economic benefit of a new LD vaccine. 
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Lyme disease (LD) is a bacterial illness primarily caused by infection with 
Borrelia burgdorferi, which is mainly transmitted by the bite of infected Ixodes scapularis 
ticks in the United States (U.S.). This multi-system disease is the most commonly 
reported vector-borne disease in the U.S. [1, 2]. Incidence is highest among children 
aged 5-10 years and adults aged 45-55 years [1]. Cases primarily occur in the 
northeastern, mid-Atlantic, and upper-midwestern states, though there is spatiotemporal 
variation in risk within these areas, depending on local ecology and human behavior [3, 
4]. Incidence is increasing as the range of I. scapularis expands from historical foci and 
human development intensifies in tick habitat [1, 5].  
Annually, over 30,000 cases are reported to the Centers for Disease Control and 
Prevention (CDC), but recent studies have provided evidence that the true number of 
cases is estimated to be over 300,000 each year [6, 7]. This disease burden represents 
considerable direct, and presumably, indirect costs to U.S. society [8], though existing 
economic studies lack comprehensive estimates [7-10]. Studies evaluating currently 
available prevention methods (e.g., repellent use, yard-based pesticides) have not 
demonstrated an effect on disease reduction [11-16]. The inability of these measures to 
stem rising LD incidence highlights the need for a prevention modality suitable for use at 
the population level, such as a vaccine [17].  
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A LD vaccine was available 1998 – 2002 in the U.S. until it was voluntarily 
discontinued by the manufacturer due to low demand caused by a number of factors, 
despite it being both safe and effective [18-20]. Since then, the number of LD cases 
reported annually has nearly doubled [21]. New vaccine candidates are currently in 
development [22-25] with potential availability as early as 2022. However, before any 
future LD vaccine can be recommended by the Advisory Committee on Immunization 
Practices (ACIP), current estimates of disease cost, potential vaccine uptake, and 
economic evaluation of a hypothetical vaccination strategy are needed [26, 27].  
Summary of Aims 
To address these research gaps, the specific aims of this dissertation are as 
follows: 
Aim 1: Estimate the per-patient cost of Lyme disease and evaluate factors associated 
with cost.  
I used a prospective, cost of illness study design to estimate the total costs 
incurred due to incident LD using a societal perspective (Chapter 3). Data were 
collected from participants and their providers to estimate medical costs, non-medical 
costs, and productivity losses attributable to LD in endemic states. Recruitment took 
place among physician-diagnosed, reported LD cases in Connecticut, Maryland, 
Minnesota, and New York. This Aim focused on three objectives: 1) Estimate the out-of-
pocket cost of LD per patient; 2) Estimate the total societal cost of LD per patient; and 
3) Evaluate associations between total societal cost per patient and the following 
independent variables of interest: LD disease category (confirmed localized, confirmed 
disseminated, or probable disease), age group, gender, and state. This Aim addresses 
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gaps in the existing literature by providing updated, comprehensive cost estimates from 
several LD endemic states using primary data sources. The results can be used in 
future economic evaluations of LD prevention methods, such as in the cost-benefit 
analysis of a LD vaccine strategy described in Aim 3 (Chapter 5) below. 
Aim 2: Estimate uptake of a potential Lyme disease vaccine and evaluate factors 
associated with willingness to be vaccinated.  
I conducted a cross-sectional, population-based survey of persons living in four 
LD endemic states to address the following objectives (Chapter 4): 1) Estimate the 
proportion of people in Connecticut, Maryland, Minnesota, and New York who would 
receive a vaccine that protects against LD if one were available; and 2) Evaluate 
associations between age, gender, state, LD vaccine cost concerns, LD vaccine safety 
concerns, and clinician LD vaccine recommendation with willingness to receive a LD 
vaccine. This estimate of vaccine uptake can be used for future economic evaluations 
for a LD vaccine, as is done in the cost-benefit analysis of a LD vaccine strategy 
described in Aim 3 (Chapter 5) below. Our characterization of the factors associated 
with willingness to receive a LD vaccine is the first of its kind and directly informs 
communication efforts with clinicians and the public to increase awareness and uptake 
of a future vaccine. 
Aim 3: Estimate the net cost of a Lyme disease vaccination strategy. 
I conducted a cost-benefit analysis using a decision-analytic model to estimate 
the net cost of vaccination against Lyme disease (Chapter 5). This Aim focused on the 
following objectives: 1) Estimate the net cost of vaccination; and 2) Evaluate which 
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variables have the greatest impact on the net costs of vaccination. The probability and 
cost estimates used in this analysis were derived from primary sources (Aims 1 and 2) 
and secondary sources (surveillance data, published literature). These results may be 
used in ACIP recommendations regarding a potential LD vaccine, and the model can be 
modified as more specific parameters for vaccine candidates become available. 
An effective human LD vaccine may be the only intervention able to make a 
substantial impact on disease reduction, but several research gaps must be addressed 
if a new vaccine is to be successful. This complementary suite of Aims provides new 
information on the economic burden of LD, willingness to receive a LD vaccine, and the 
net costs of a hypothetical vaccination strategy. These results will inform 
recommendations and public health communications for a LD vaccine when one 
becomes available. 
My role in the research 
 Since 2012, I have served as the study coordinator for the TickNET research 
program based out of the Bacterial Diseases Branch, Division of Vector-Borne Diseases 
at the Centers for Disease Control and Prevention (CDC). TickNET is a public health 
network composed of researchers at state health departments, universities, and the 
CDC who collaborate on tickborne disease research and surveillance [51]. The projects 
described in chapters 3 and 4 were conducted by a team of TickNET researchers in 
Connecticut, Maryland, Minnesota, and New York during 2014 – 2018. During this time, 
I was responsible for protocol development, gaining regulatory approvals, coordinating 
activities among the TickNET sites, data storage and management, data analysis, 
report writing, and preparing publications for both of these projects. The research 
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described in Chapter 5 was conducted solely by me, as part of my regular duties at 
CDC, yet it was only made possible with use of the primary data collected through the 
TickNET research described in chapters 3 and 4. In 2018, I received a scholarship from 
CDC to complete my PhD in epidemiology at Colorado State University (CSU). Both 
CSU and CDC allowed me to use the research I had conducted in my role with TickNET 
for my doctoral dissertation. 
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Background on the burden of Lyme disease 
Lyme disease (LD) is a tickborne bacterial illness caused by infection with 
Borrelia burgdorferi sensu lato genospecies complex [28, 29]. In the United States 
(U.S.), Lyme disease is primarily caused by infection with B. burdgorderi sensu stricto, 
and occasionally by the recently discovered B. mayonii [30]. These bacteria are mainly 
transmitted by the bite of infected Ixodes scapularis nymphal ticks in the Northeast, Mid-
Atlantic, and Upper Midwestern and, more rarely, by I. pacificus ticks in the Pacific 
Northwest of the U.S [31]. However, there is spatiotemporal variation in risk within these 
regions, depending on local ecology and human behavior [3, 4]. The bacteria are 
maintained in a complex ecologic cycle primarily involving Ixodes spp. ticks, rodent 
reservoirs of the bacteria upon which the ticks feed, and large mammal hosts 
responsible for sustaining tick populations. Humans are incidental hosts, with increasing 
exposure due to the range expansion of I. scapularis from historical foci and 
intensification of human development in tick habitat [1, 5].  
LD consistently ranks within the top 10 nationally notifiable conditions and is the 
most commonly reported vector-borne disease in the U.S. [1, 2]. Annually, over 30,000 
cases are reported from state and local public health surveillance authorities to the 
Centers for Disease Control and Prevention (CDC) [1]. Surveillance data show a 
bimodal peak in incidence among children aged 5 – 10 years and adults aged 45 – 55 
years, along with a slight male predominance in most age groups [1]. However, 
surveillance for LD is resource-intensive due to the need for accompanying clinical 
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information with laboratory reports (described below), and reporting and surveillance 
practices vary across jurisdictions. As such, underreporting of LD has been recognized 
for decades [32-36]. Recent studies using laboratory testing data and insurance claims 
data have provided evidence that the true number of cases is estimated to be over 
300,000 each year [6, 7], resulting in a substantial disease burden to U.S. society [8].  
Early symptoms of localized infection include a characteristic bulls-eye rash 
known as erythema mirgrans (EM) as well as flu-like symptoms such as fever, 
headache, fatigue, myalgia, and arthralgia [29]. If left untreated, disseminated disease 
can cause facial paralysis, arthritis, neurologic involvement, and rarely, cardiac 
involvement, though this can be life threatening. LD is typically treated with a 10 – 14-
day course of oral antibiotic, though treatment of late-stage disease may require more 
aggressive antibiotic therapy. Most patients will experience a full recovery after 
antibiotic treatment, although a small proportion (5 – 10%) may continue to experience 
symptoms related to disease sequelae for months to years [29, 37]. If these symptoms, 
usually subjective complaints, persist in a confirmed LD patient for at least six months 
following antibiotic treatment, the patient is said to have post-treatment LD syndrome 
(PTLDS) [37, 38]. With PTLDS there is no evidence of ongoing infection, and no benefit 
has been found for long-term treatment with antibiotics [39-42]. This syndrome is 
distinct from the term “chronic Lyme disease” used informally by some patients, 
clinicians, and patient advocates, and for which there is no agreed-upon definition. The 
controversial term is often applied by those outside of mainstream medical practice to 
patients with subjective symptoms and no evidence of infection, and diagnosis and 
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treatment of “chronic Lyme disease” has been linked to unproven, sometimes harmful, 
treatments [43-45].  
For cutaneous manifestations of LD, i.e., EM, diagnosis of LD can be made 
based on clinical findings alone in areas endemic for LD. For non-cutaneous 
manifestations, diagnosis of LD is primarily supported by serologic testing [29]. Current 
recommendations for laboratory testing include using a two-step process [46]. The first 
step involves a sensitive enzyme immunoassay or immunofluorescences assay; if this 
test is negative, no further testing is necessary. If the first test is positive or equivocal, a 
second step involving either a western immunoblot assay or an additional enzyme 
immunoassay is recommended. 
The national surveillance case definition for LD includes criteria for confirmed or 
probable cases [47]. A confirmed case of LD is defined as follows: 1) a case of EM ≥ 5 
cm with a known exposure; or 2) a case of EM without a known exposure but with 
laboratory evidence of infection; or 3) a case with at least one late manifestation 
(arthritis, lymphocytic meningitis, cranial neuritis or facial palsy, radiculoneuropathy, 
encephalomyelitis, or second or third degree heart block) that has laboratory evidence 
of infection. A probable case is defined as follows: any other case of physician-
diagnosed LD that has laboratory evidence of infection; additional clinical information 
may or may not be present. 
Current prevention options 
Available prevention methods include personal measures such as tick checks, 
repellent use, permethrin treated clothing, avoidance of tick habitat, and showering or 
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bathing after being in tick habitat. Current prevention options also include environmental 
controls such as yard-based acaricide treatments, host-targeted acaricide treatments, 
and landscape modifications [48]. These personal and environmental measures have 
been the mainstay of LD prevention for the past several decades. However, studies 
evaluating personal protective measures have shown that use is inconsistent, with 
minimal or no effect on disease reduction [11-16]. More recent randomized controlled 
trials have shown that yard-based and host-targeted acaricide treatments failed to 
reduce human tickborne disease ([49], Hinckley et al., in prep). The inability of these 
personal and yard-based measures to stem rising LD cases highlights the need for a 
prevention modality suitable for use at the population level, namely, a LD vaccine. 
Lyme disease vaccines: past, present, and future 
Two safe and effective vaccines for LD were independently developed and 
completed Phase III clinical trials in the 1990s. ImmuLyme was developed by 
Connaught Laboratories, and LYMErix was developed by SmithKline Beecham 
Pharmaceuticals. Both were designed to confer protection based on a recombinant 
outer surface protein A (OspA) of B. burgdorferi; the vaccines utilized a novel mode of 
action by stimulating human antibodies to OspA, which then neutralized B. burgdorferi 
spirochetes in the gut of the tick during its blood meal, thus preventing transmission of 
B. burgdorferi from the tick to the human host [50]. Two multi-center, randomized, 
placebo-controlled trials evaluated the efficacy of a 30 μg, three-dose series of each 
vaccine; they were both well tolerated, with only mild, self-limited reactions and no 
significant increase in arthritis or neurologic events in those vaccinated [51, 52]. Efficacy 
after two doses ranged from 40 – 68%; after three doses, efficacy increased to 76 – 
      
 
10 
92%. However, Connaught Laboratories never sought licensing by the Food and Drug 
Administration (FDA) for ImmuLyme. LYMErix sought and received licensing from the 
FDA, and the vaccine was available for persons aged 15-70 years from 1998 until 2002 
in the U.S. [18, 19, 51, 52]. During the vaccine’s availability, no effectiveness studies 
were conducted to determine its impact on disease incidence, and duration of immunity 
was not evaluated past three years post-vaccination. 
In February 2002, LYMErix was voluntarily discontinued by the manufacturer, 
reportedly due to poor sales [20]. However, several factors have been highlighted as 
reasons contributing to low demand [50, 53-55]. There was vocal opposition by some 
LD advocacy groups who claimed that the vaccine caused Lyme arthritis, and a class-
action lawsuit ensued. These claims were based on patient testimonies of vaccine harm 
and pointed to a mainstream scientific hypothesis at the time that OspA might cause 
treatment-resistant LD arthritis via molecular mimicry; the OspA protein was similar to a 
human protein, LFA-1, which was posited to play a role in autoimmune arthritis [56].  
This molecular mimicry hypothesis was never proven, and post-licensure safety studies 
and CDC’s Vaccine Adverse Events Reporting System (VAERS) never found evidence 
for vaccine-induced, LD arthritis, leading to the conclusion that LYMErix was indeed a 
safe vaccine, although sales had already begun to decline at the time of these 
determinations [53, 54].  
Further, some have cited hedged recommendations for approval by the FDA and 
tepid, cumbersome recommendations for clinical use by the Advisory Committee on 
Immunization Practices (ACIP) at CDC as reason for low demand by physicians and the 
public [17, 19, 57]. The ACIP, composed of immunization experts from inside and 
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outside CDC, makes national recommendations for the use of licensed vaccines, which 
are based on epidemiology, public acceptance, public health impact, cost, vaccine 
supply, and other factors beyond the safety and efficacy data used for FDA approval 
[26, 27, 58]. These recommendations become CDC policy upon publication in the 
Morbidity and Mortality Weekly Report and are the primary guide for clinicians in 
vaccination decisions for individual patients. At the time of LYMErix’s licensure, cases 
were not widespread, and incidence of 0.01 occurred in only a few highly endemic 
counties; in addition, LD is non-communicable, so vaccination against it would not offer 
the additional benefit of herd immunity that is a feature of most other vaccines [50, 59]. 
These facts limited the public health impact of a LD vaccine. Several cost-effectiveness 
analyses (CEAs) concluded that the vaccine was only cost-effective for residents in high 
incidence areas who had elevated individual risk for LD [60-62].  These conclusions had 
a major role in informing ACIP’s recommendations for use of the LYMErix vaccine [19]. 
In addition, it was not available for children under 15 years, the highest risk age group; it 
was presumed that booster doses would be needed; and many saw LD as a mild, easily 
treatable disease that could be prevented with other options [50]. Lastly, LYMErix’s 
marketability was not helped by the coincident rise of the most recent anti-vaccination 
movement in modern history [55].  
Since LYMErix’s withdrawal, the number of LD cases reported annually has 
nearly doubled [21]. After almost two decades without an effective prevention method, a 
new vaccine candidate called VLA15 [22-25] is being developed by the French biotech 
company, Valneva, in partnership with Pfizer [63-65]. Using a similar, recombinant 
OspA technology as past LD vaccines, this vaccine candidate is being evaluated as a 
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three-dose series, but with several important improvements. First, it is being evaluated 
for use in the general population, including children aged 2 years and older. Second, it 
is designed to protect against the primary LD causing strains found in both the U.S. and 
Europe. Third, the alleged arthritis-causing epitope of OspA has been removed. 
Randomized, observer-blind, placebo-controlled Phase II trials were completed in 2020 
in LD endemic areas of the U.S. and Europe, with results showing both a favorable 
safety profile and high immunogenicity across all tested age groups. If successful, 
VLA15 may be licensed for use as early as 2024.  
In addition, a passive vaccination approach using a single monoclonal antibody 
administered annually is also in development [66-68]. This product, called Lyme pre-
exposure prophylaxsis (Lyme PrEP), is being developed by MassBiologics, a non-profit 
vaccine manufacturer overseen by the University of Massachusetts Medical School. 
MassBiologics plans to initiate Phase 1 trials in 2020 with potential availability in 2022 
[66]. 
Data gaps 
In the absence of other validated prevention methods, an effective human LD 
vaccine may be the only intervention able to make a substantial impact on disease 
reduction. However, several research gaps must be addressed if a new vaccine is to be 
successful. While recent studies have shown that the disease burden of LD is high, the 
current economic burden of LD to patients and society in the U.S. is unknown [69]. 
Estimating this aspect of disease burden is crucial for future health economic 
evaluations of a vaccine.  Further, while rising LD incidence would ostensibly result in 
increased demand for a new vaccine, the controversial climate surrounding LD [45], the 
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failure of LYMErix [50, 55],  and general vaccine hesitancy among some groups [70-73] 
necessitate further investigation into the acceptability of a LD vaccine among potential 
consumers. This information will be critical for targeting vaccine communications to 
patients and providers pre- and post-licensure. Finally, as was seen in the ACIP 
recommendations for LYMErix, cost is an important factor in making guidelines for use 
of a vaccine. When the CEAs for LYMErix were conducted, incidence rates close to 
0.01 occurred only in a few counties in the northeastern U.S., which limited the overall 
economic benefit of the vaccine. With the number of reported cases currently growing 
and recent studies estimating true cases at more than 300,000 annually [6, 7], there are 
now many more areas of the U.S. where incidence meets or exceeds 0.01, warranting 
an updated economic evaluation for a potential, new LD vaccine.  
Gap1: Economic burden of Lyme disease 
Cost of illness studies 
Cost of illness studies are economic evaluations that show the impact of an 
illness, beyond morbidity and mortality, by presenting disease burden in monetary terms 
[74, 75]. Researchers conducting these essentially descriptive studies aim to itemize, 
value, and sum the costs of an illness from different payer perspectives. These different 
perspectives may include those of the patient, healthcare provider, third-party payer, 
government, employer, or society as a whole; for the societal perspective, all costs of an 
illness are taken into account, regardless of who pays those costs [76]. Cost of illness 
studies may be prevalence-based, wherein the costs attributable to an illness for any 
cases within a predetermined time period (usually a year) are collected, or incidence-
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based, wherein costs attributable to new cases only are collected from onset of disease 
to recovery or death [77]. Cost of illness studies may also be conducted retrospectively 
or prospectively. Retrospective studies require that sufficient data are available, and this 
methodology is more efficient for diseases of long duration. Prospective studies are 
better suited for diseases of short duration and allow for data collection systems tailored 
to the illness under investigation; non-medical costs and productivity losses are more 
easily measured with this methodology. Costs are typically categorized as direct 
(including medical and non-medical costs), indirect (i.e., productivity losses), and 
intangible costs (e.g., the psychosocial cost of pain and suffering), though intangible 
costs are difficult to quantify and are typically omitted from cost of illness studies [78].  
Some economists are critical of cost of illness studies because many of the 
included costs do not reflect true opportunity costs in terms of welfare economics 
because healthcare markets often do not operate perfectly (or fail), compared to other 
markets [79]. Further, many cost of illness studies use the human capital approach to 
value productivity losses (vs. willingness-to-pay methods). Lastly, retrospective studies 
can potentially suffer from recall bias and high-level approximation [77]. Despite these 
criticisms, prospective, incidence-based cost of illness studies, while demanding in 
terms of data collection, can be very detailed and highly informative. The results help 
inform public health resource use by allowing for relative comparisons of the economic 
burden of different diseases. Further, incidence-based cost of illness results provide 
estimates of the cost savings per case averted (i.e., the potential benefit of an 
intervention), which can be used in cost-benefit analyses [77]. 
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Economic evaluations for Lyme disease 
  Previous studies have estimated certain components of the costs of LD morbidity 
in the U.S., though very few have made comprehensive evaluations using an incidence-
based, cost of illness approach [7-10, 33, 69, 80, 81]. Two older studies conducted 
more comprehensive analyses from the societal perspective for the total cost of LD in 
the U.S., including direct and indirect costs, albeit utilizing different methodologies. 
Maes et al. (1998) conducted a retrospective, incidence-based cost of illness study by 
modeling total U.S. expenditures for LD based on disease outcome probabilities 
developed by an expert panel, cost data from medical claims of the privately insured, 
and productivity losses from the National Health Interview Survey (NHIS). The authors 
estimated a total societal cost of $843M (2020 USD) annually [9, 82]. This study was 
limited by the lack of research at the time of publication on probabilities for disease 
outcomes, necessitating numerous assumptions in the model. In addition, costs were 
extracted for LD patients based on the International Classification of Diseases, Ninth 
Revision, Clinical Modification (ICD-9-CM) code for LD, 088.81, which has been shown 
to have low sensitivity and specificity in identifying true LD cases. Lastly, indirect costs 
were identified from the NHIS based on ICD-9-CM codes for symptoms related to LD 
(e.g., dermatologic symptoms), but not specifically for LD patients. Zhang et al. (2006) 
collected direct and indirect costs from LD patients identified via health records in a 
retrospective, incidence-based study conducted in five counties in MD [10]. LD patients 
were categorized into five diagnosis groups: clinically defined early-stage LD, clinically 
defined late-stage LD, suspected LD, tick bite, and other related complaints. Charges 
were used to estimate direct medical costs for 3,415 patients; questionnaires assessing 
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patient out-of-pocket medical costs, non-medical costs, and productivity losses were 
available for 284 of these patients. The authors estimated a mean total cost attributable 
to LD at $3,030 and a median cost of $433 per patient; they estimated an aggregate 
cost to U.S. society of $298M (2020 USD) annually, though this estimate was based on 
reported cases in 2002, not accounting for underreporting. This study was limited in 
scope geographically and may not reflect costs in other endemic areas. Further, indirect 
cost data were only available for 8% of the study population but were extrapolated to 
the entire study population for total cost; this approach may have affected the validity of 
the results, though whether it resulted in an over- or under-estimation of costs is 
unclear.  
A more recent, retrospective, incidence-based study by Adrion et al. (2015) used 
nationwide private insurance claims data to compare direct medical costs of LD cases 
(n = 52,795) with matched controls (n = 263,975) from 2006 – 2010 using the 
healthcare payer perspective [8]. The authors estimated an increase of $3,305 (2020 
USD) per patient in direct medical costs attributable to LD over a 12-month period 
compared with matched controls. The authors extrapolated these results to the 
estimated number of cases per year from Hinckley et al. (2014) for an estimated total 
aggregate cost per year of $793M (2020 USD) [7, 8]. This study is limited in that LD 
patients and controls were restricted to persons under 65 years of age with commercial 
health insurance plans; direct costs for those older than 65 years with non-private 
insurance may be very different due to other comorbidities or likelihood of having public 
insurance (i.e., Medicare), so results may not be generalizable to all LD patients. 
However, a strength of this study is that authors evaluated costs for LD patients from 
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across the U.S.; costs and healthcare utilization for LD in areas where the disease is not 
endemic likely varies from that in endemic areas. In this way, the results are more 
representative of nationwide costs. 
Hinckley et al. (2014) conducted a retrospective study to estimate the total direct 
cost of LD testing in the U.S. as charged by large commercial laboratories [7]. The 
authors reported a national, annual cost of $596M (2020 USD) for 3.4M LD diagnostic 
tests representing approximately 2.4M people; only 10 – 18.5% of testing represented 
true infections, suggesting that many patients undergo unnecessary, costly testing. 
Strickland et al. (1997) and Fix et al. (1998) drew similar conclusions from their 
retrospective studies conducted in Maryland in the 1990s [80, 81]. Strickland et al. 
estimated an annual testing burden for LD of 30,000 tests at a cost of $3.5M (2020 
USD) in direct medical costs in Maryland alone, much of which was for inappropriate 
use of serologic testing as a test of cure after treatment. In a smaller study of 232 
patients, Fix et al. estimated that serologic testing costs for LD accounted for 33% of the 
total direct medical costs among patients, with the largest share (43%) of testing 
conducted inappropriately for those with tick bite. 
There are several more comprehensive cost of illness studies for LD conducted 
from the societal perspective in Europe [83-85]. In a recent study in the Netherlands, 
Van den Wijngaard, et al. (2017) used a societal perspective to estimate a total cost of 
$145 for patients with EM only and $6,858 (2020 USD) for those with disseminated 
Lyme borreliosis for an aggregate national cost of $24.8M (2020 USD) [85]. Joss et al. 
(2002) reported an annual cost of $788,705 USD for LD in Scotland, while Lohr et al. 
(2015) estimated an annual national economic burden of $43.8M USD in Germany 
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(2020 USD) [83, 84]. Comparability to U.S. studies may be limited by differences in 
disease incidence, healthcare financing systems, or variations in clinical manifestations 
due to infection with different B. burgdorferi sensu lato strains [83-85]. 
In summary, most existing cost of illness studies report direct medical costs but 
lack data on productivity losses and non-medical costs [8, 10, 80, 81]. Several studies 
were conducted two decades ago in a small number of Maryland counties where LD 
was emerging [10, 80, 86], and the age of these studies and limited geographic scope 
prevents generalizability to other endemic areas. More recent studies have used 
diagnosis codes, e.g., ICD-9-CM, to identify LD patients from insurance claims 
databases. However, the low sensitivity and specificity of these codes in identifying true 
cases [87, 88] may lead to incorrect estimates of direct medical costs attributable to LD. 
Further, data available from insurance claims is often restricted to those with private 
insurance who are under 65 years of age, again, limiting generalizability. The research 
project described in Aim 1 (Chapter 3) addresses these gaps by conducting a 
prospective, incidence-based, cost of illness study among physician-diagnosed, 
reported LD cases in four high incidence states to estimate the total direct and indirect 
cost per patient from both the societal as well as the patient perspectives. 
Gap 2: Acceptability of a potential Lyme disease vaccine 
As noted above, LD vaccine candidates are in development that have the potential 
to substantially reduce disease incidence. However, if the pitfalls of the failed LYMErix 
vaccine are to be avoided, it is necessary to understand motivators for and barriers to 
receiving a new LD vaccine among potential consumers. Lessons may be drawn from 
general vaccine acceptability/hesitancy research, but specific considerations arise with 
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a LD vaccine. For example, LYMErix is notable for being the only vaccine withdrawn 
from the U.S. market that was proven to be both safe and effective [50, 55]. Further, 
vaccination against LD will not prevent infections with other pathogens transmitted by 
I.scapularis ticks such as Anaplasma phagocytophilum, Babesia microti, Powassan 
virus, and B. miyamotoi. While these diseases are rare compared to LD [2], this fact 
may influence potential consumers’ view of acceptability of a LD vaccine given that the 
same prevention measures will still be required to prevent other I. scapularis transmitted 
infections. In addition, there are discrepancies in how potential consumers view how 
easily detected, how severe, and how treatable the disease is, with some viewing it as 
mild and easily treatable and others believing it to be a debilitating, life-long illness [43, 
45]. It is unclear how these discordant views may affect overall demand for a LD 
vaccine.  
General vaccine hesitancy considerations in U.S. 
The term “vaccine-hesitant” includes those who refuse some or all vaccines, 
those who delay or use an alternative schedule of vaccination, or even those who 
accept all vaccines but still harbor concerns [73]. The causes of vaccine hesitancy are 
complex and varied, but many stem from a perception of the risk of vaccines as greater 
than they actually are, largely due to societal unfamiliarity with the diseases vaccines 
prevent (i.e., lower perceived risk of contracting a vaccine preventable disease and 
lower perceived risk of the severity of vaccine preventable diseases) [89]. Further, 
higher risk perception is attributable to the compulsory nature of some vaccines; the 
coincidental temporal relationship between vaccination and other, unrelated adverse 
health outcomes; general lack of trust in corporations and public health agencies; and 
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an abundance of misinformation about vaccines on the internet [73]. The upshot is that 
for any vaccine, including a potential LD vaccine, safety and efficacy concerns are 
paramount among potential consumers and must be adequately addressed to increase 
acceptability [71-73, 90-94]. 
While vaccine hesitancy is certainly a barrier to receiving vaccinations, there are 
also important logistical and structural barriers to receiving vaccinations by patients that 
should also be considered with a potential LD vaccine. The uninsured, underinsured, 
and those with interruptions in insurance experience lower coverage of recommended 
vaccines [95], particularly among adults where there are fewer safety nets compared to 
childhood vaccinations (e.g., health department clinics). Other structural barriers include 
the fact that many are simply not aware of non-compulsory vaccine recommendations; 
not all ACIP-recommended vaccines for adults are covered by public and private 
insurance; many providers lack resources to properly store, recommend, and deliver 
adult immunizations; immunization histories can be difficult to access or determine; and 
finally, convenient locations for immunization in nontraditional settings (e.g., workplaces, 
pharmacies) are often not readily available [96]. In addition, demographic disparities in 
vaccination coverage are well documented among adults and children; these disparities 
may be related to hesitancy and/or structural barriers [70, 71, 90, 97-99]. 
Lyme disease vaccine acceptability studies 
  Two vaccine acceptability studies were conducted for LYMErix when it was 
available. A 2002 study among parents (n = 186) in Nassau County, New York 
evaluated whether parents would request the LYMErix vaccine for their children, if it 
became available, and what factors might influence this decision. The vast majority of 
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parents reported that they would “definitely” (23%) or “likely” (65%) request it, followed 
by those “unlikely” (9%) to request it and those who would not (3%) [93]. Parents with 
greater concern for LD, those with children who participated in high-risk activities, and 
those with lower LD knowledge scores were more likely to request the vaccine for their 
children. Parents also reported that clinician recommendation for the vaccine would 
have the most influence on their decision (71%), followed by personal research (23%), 
and media reports (6%) [93]. Another study evaluated a LYMErix vaccination program 
among New York State Department of Health employees (n = 190) at risk for 
occupational tick exposure. This study aimed to assess attitudes affecting the 
employees’ vaccination decision. While only 16% of employees chose to receive 
vaccination, they did so because of an anticipated risk of tick exposure (e.g., working in 
leaf litter or brushy areas). Among those who declined vaccination, the majority (64%) 
reported safety as a major concern, followed by the novelty (56%) and efficacy (48%) of 
the vaccine [94]. These studies shed light on motivators for LD vaccination specifically 
(e.g., hypothetical availability for children) and barriers (e.g., safety and efficacy 
concerns). However, both studies were small and conducted among very specific 
populations; as such, there is little empirical research available to adequately assess 
the exact reasons for low acceptability of the LYMErix vaccine among the broader 
population living in endemic areas. 
There has been limited research conducted on the acceptability of a potential, new 
LD vaccine. In a 2016 convenience sample survey conducted among residents (n = 
1883) in Connecticut and Maryland counties with a high incidence of LD, Niesobecki et 
al. (2019) found that the majority of respondents were likely to be vaccinated. 
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Specifically, 49%  reported being “very likely”, followed by 35% being “somewhat likely”, 
8% being “somewhat unlikely”, and 7% being “very unlikely” to receive a LD vaccine 
[100]. Similarly, in a nationwide population-based survey conducted in 2014 and 2015, 
Nawrocki et al. found that 65% of respondents in high incidence states would be “likely” 
to receive a LD vaccine [101]. Additionally, a qualitative research study conducted in 
2018 using focus groups comprised of those at high risk for LD showed that 57% would 
be “very likely” to receive a LD vaccine (Devchand et al, submitted).  
While these concordant results across different study designs are encouraging for 
the acceptability and potential uptake of a new LD vaccine, only one of the three studies 
was population-based. Further, gaps remain regarding understanding the motivators for 
and against receipt of a LD vaccine. The research project described in Aim 2 (Chapter 
4) addresses these gaps using a cross-sectional, population-based survey of persons 
living in four states with a high incidence of LD to estimate the proportion who would be 
willing to receive a potential LD vaccine if one were available and to evaluate factors 
associated with willingness to vaccinate (e.g., demographic characteristics and specific 
vaccine concerns). The estimate of vaccine uptake can be used for future economic 
evaluations for a LD vaccine, as in Aim 3 (Chapter 5), and the characterization of 
factors associated with willingness to vaccinate will inform future communication efforts 
with clinicians and the public to increase awareness and uptake of a vaccine. 
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Gap 3: Economic benefit of a potential LD vaccine 
Key features of economic evaluations for health interventions 
There are three main approaches to health economic evaluation: cost-effectiveness 
analysis (CEA), cost-utility analysis (CUA), and cost-benefit analysis (CBA). All three 
are comparative analyses that use the costs (i.e., monetized resource use) of an 
intervention as inputs and the benefits of that intervention as outputs (e.g., improved 
health, healthcare savings) [102, 103]. These analyses differ with respect to how 
benefits are defined. CEA defines benefits as a standardized unit of non-monetary 
effectiveness, such as number of cases treated, cases prevented, or lives saved. CUA 
is a form of CEA in which the unit of effectiveness is a quality-adjusted life year (QALY) 
or disability-adjusted life year (DALY), which incorporates time and utility [104]. 
Limitations of CEA and CUA include the potential for great variability in estimation of the 
measures of effectiveness [103] and inability to capture non-health benefits, i.e., non-
health cost-savings [105]. CBA, on the other hand, defines effectiveness of the health 
intervention in monetary terms, that is, monetary value must be assigned to life or 
health status. While the need to monetize health status has been criticized by those 
who view life as invaluable, CBA has the advantage of allowing for cost comparison 
across a range of interventions and illnesses [105]. Further, CBA is the recommended 
approach for public health vaccines to determine whether they are worthwhile [102]. 
For all three types of health economic evaluations, it is important to evaluate 
uncertainties and variabilities in the parameters used to understand how valid the data 
are or how robust the conclusions [103]. Sensitivity analysis may reveal areas where 
more research is necessary to accurately estimate the variable to which the result, e.g., 
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net cost of an intervention, is sensitive [106]. Sensitivity analysis usually takes one of 
two forms: deterministic sensitivity analysis (DSA) or probabilistic sensitivity analysis 
(PSA). In DSA, the most common form of sensitivity analysis, one or more parameters 
in an economic evaluation is varied across a plausible range. With one-way DSA, each 
parameter is varied individually while the other parameters are held at their base-case 
specification; in this way, the impact on results can be evaluated separately for each 
parameter. In multi-way DSA, two or more parameters are varied across plausible 
ranges at the same time; however, variation of many parameters can complicate 
presentation of results. PSA requires that plausible ranges plus probability distributions 
be specified, then Monte Carlo simulations simultaneously select values at random for 
each parameter from each specified distribution; the result of the economic evaluation 
for each simulation is stored and results in its own probability distribution. Other forms of 
sensitivity analysis include threshold analysis and analysis of extremes. In threshold 
analysis, the goal is to identify the value of one or two parameters above or below which 
the conclusion about the study’s result will change (e.g., the point at which an 
intervention goes from having a net cost to net savings). This type of sensitivity analysis 
is particularly useful when a certain parameter is unknown, such as the price of a 
vaccine before it is available. Lastly, analysis of extremes, sometimes referred to as 
“worst/best case analysis”, uses the extreme estimates of each parameter under either 
optimistic or pessimistic assumptions (e.g., a low cost, high effectiveness scenario or a 
high cost, low effectiveness scenario, respectively). 
Decision analysis refers to the use of a systematic, quantitative approach to 
decision-making under uncertainty, and this methodology has been increasingly used to 
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evaluate public health and clinical interventions, including health economic evaluations 
[107]. Decision-analytic models often take the form of a decision tree or a Markov 
model, and they can be used in cost-benefit analyses to estimate the net costs (or 
savings) of an intervention, such as vaccination, while incorporating uncertainty. 
Decision tree modeling presents a mathematical structure for the decision of interest, 
the probabilities of resultant events, and disease states over a certain time horizon 
[107]. This approach is particularly appropriate for acute, non-communicable diseases 
occurring over a short, fixed time horizon, such as LD. A decision tree is composed of 
branches and nodes, which are classified as either decision, chance, or terminal nodes. 
The terminal nodes represent the outcomes of interest at the end of a specified time 
horizon. 
Economic evaluations for a Lyme disease vaccine 
Three CEAs were conducted for the LYMErix vaccine from 1999 – 2002 in the 
U.S., all comparing a vaccination strategy with a no vaccination strategy and using 
vaccine performance parameters of the LYMErix vaccine available at the time [60-62]. 
Meltzer et al. (1999) used a decision-analytic model to estimate the main outcome of 
the cost per case averted in a vaccination strategy that assumed universal vaccination 
of the cohort and included a yearly booster [60]. Parameters included the cost of 
vaccination, effectiveness of vaccination, annual probability of contracting LD (i.e., 
incidence), direct and indirect costs of treating LD (including early LD or sequelae and 
associated costs), probability of successfully treating early LD, and the probability of 
sequelae. Because of uncertainty in the parameter estimates due to lack of data at the 
time, particularly for the cost of the vaccine and the cost of treating disease, the authors 
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defined the probability distributions of these parameters and employed Monte Carlo 
simulations to generate a probability distribution of the cost per case averted and 
resulting summary statistics. Their main finding was a cost per case averted of $10,143 
(USD 2020) annually with a vaccination cost of $100 per year, vaccine effectiveness at 
0.85, and an incidence of 0.01 [60]. The authors concluded that the incidence of LD is 
the most important factor influencing the cost per case averted, followed by the cost of 
treating sequelae and the probability of successful early treatment of LD. However, 
many of the model parameters changed the net results from cost to savings upon 
variation; therefore, the authors also noted that a “single answer regarding the cost 
effectiveness of vaccinating a person against Lyme disease cannot be calculated” [60]. 
In terms of policy implications, i.e., ACIP guidelines for use of LYMErix, the authors 
suggested that use of the vaccine should be based on a combination of community- and 
individual-level risk. The main limitation of this study was the lack of data available on 
the cost of the vaccine and the cost of treating LD, resulting in a high level of uncertainty 
in the results. 
Shadick et al. (2001) similarly used a decision-analytic model to evaluate the cost 
effectiveness of a vaccination strategy, but the authors’ main results included the 
number of cases averted, cost per case averted, and cost per quality-adjusted life-year 
(QALY) gained. Other differences from Meltzer et al. included the use of a Markov 
model to simulate a cohort of individuals through 10 seasons, and an additional 
parameter of vaccine compliance, varied by three shots (full compliance), two shots, or 
one shot. The authors assigned a base-case estimate and plausible range to each 
parameter in the model and performed DSA. The quality of life weights used in the 
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estimate of QALY gained were derived from a random sample of 105 residents from a 
high incidence area. At a vaccination cost of $150 and an incidence of 0.01, the authors 
estimated that 202 cases of LD would be averted during a 10 year period for every 
10,000 persons vaccinated, which results in a cost per case averted of $11,346 and a 
cost per QALY gained of $118,507 (USD 2020) [62]. These authors also concluded that 
LD incidence had the largest impact on results, and that vaccination against LD in 
endemic areas with incidence ≥ 0.01 “compares somewhat favorably with other 
preventive treatments” [62]. The major limitations of this study again included lack of 
definitive data on the cost of vaccination or the cost of treating LD, as well as a lack of 
inclusion of indirect costs in treating LD. Incorporating the latter cost would influence 
results in favor of vaccination. 
Hsia et al. (2002) also conducted a CEA using a Markov decision-analytic model 
to estimate the cost effectiveness of LD vaccination [61]. The authors used a 
hypothetical cohort of individuals aged 15 – 70 years and a 10-year time horizon with 
yearly cycles. Two vaccine strategies were evaluated: one with an annual booster and 
one with a booster every three years. Otherwise, parameters were similar to those used 
by Shadick et al. One-way deterministic sensitivity analysis was conducted for all 
parameters, and two-way sensitivity analysis was conducted for LD incidence and 
certain components of the costs of treatment and probability of disease. In addition, 
best-case and worst-case scenarios were evaluated. The authors estimated a cost per 
case averted of $9,309 for the strategy with booster vaccination every 3 years or a cost 
of $17,975 (USD 2020) for the strategy with an annual booster [61]. Similar to the other 
two studies, the authors concluded that LD incidence was the most important factor in 
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determining cost-effectiveness for a LD vaccine, and that at > 0.01 incidence, a LD 
vaccine was potentially cost-effective, but that individual risk should be taken into 
account when recommending the LYMErix vaccine. The major limitations of this study 
again included the lack of available, comprehensive cost of illness data, most notably 
the lack of indirect costs. 
When these CEAs were conducted, incidence rates close to 0.01 occurred only 
in a few counties in the northeastern U.S., which limited the overall economic benefit of 
the vaccine. With the number of reported cases currently growing and recent studies 
estimating true cases at approximately 10 – 12 fold higher [6, 7], there are now many 
more areas of the U.S. where incidence meets or exceeds 0.01. Further, more recent 
cost of illness studies, described above and including Aim 1 (Chapter 3), allow for use of 
more robust data sources for cost parameters in future economic evaluations of a LD 
vaccine. Lastly, with two vaccines currently in development, an updated economic 
evaluation for a potential, new LD vaccine will be useful for ACIP considerations and 
recommendations, even prior to such a vaccine coming to market. In Aim 3 (Chapter 5), 
I aim to improve upon past CEAs of the LYMErix vaccine by conducting a CBA, which 
provides an estimate of the net cost (or savings) of a new, potential vaccine, plus 
identification of the most important drivers of this estimate. An additional benefit is that 
the model can be modified as more specific information on vaccine parameters for 
VLA15 or LymePrEP becomes available. 
Summary 
In the absence of other validated prevention methods, an effective human LD 
vaccine may be the only intervention able to make a substantial impact on disease 
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reduction. However, several research gaps must be addressed if a new vaccine is to be 
successful. The research described herein will provide new information on the economic 
burden of LD, willingness to receive a LD vaccine, and the net costs (or savings) of a 
hypothetical vaccination strategy. These results will inform recommendations and public 
health communications for a LD vaccine when one becomes available. 
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CHAPTER 3: THE ECONOMIC BURDEN OF REPORTED LYME DISEASE IN HIGH 





There are over 300,000 cases of Lyme disease (LD) in the United States 
annually, yet comprehensive economic evaluations are lacking. We estimated the total 
out-of-pocket and total societal cost per patient due to LD in a prospective study among 
patients in LD endemic states. Additionally, we evaluated disease and demographic 
factors associated with total societal cost. Patients had an average out-of-pocket cost of 
approximately $1,200 (median $240) and an average total societal cost of 
approximately $2,000 (median $700 (2016 USD)). Those with confirmed disseminated 
and probable disease had double the costs of those with confirmed localized disease. 
The aggregate cost of diagnosed LD could be upwards of $800 million annually in the 
United States. These findings emphasize the importance of effective prevention and 
early diagnosis to reduce morbidity and associated costs. Results can be used in cost-
effectiveness analyses of current and future prevention methods, such as a vaccine. 
 
  




Lyme disease (LD) is a bacterial illness caused by infection with Borrelia 
burgdorferi, or, less commonly, Borrelia mayonii, which is transmitted by the bite of 
infected Ixodes scapularis and I. pacificus ticks in the United States (U.S.). Early 
symptoms of LD include a bull’s-eye rash known as erythema migrans (EM) as well as 
flu-like symptoms [29]. Disseminated infection can cause neurologic, musculoskeletal, 
and cardiac complications; in rare cases, cardiac involvement can be fatal [1, 29, 108, 
109]. Most patients will experience a full recovery after antibiotic treatment, although a 
small proportion may continue to experience symptoms related to disease sequelae [29, 
37].  
LD case numbers consistently rank in the top 10 among all nationally notifiable 
conditions, and LD is the most commonly reported vector-borne disease in the U.S. [1, 
2]. Annually, over 30,000 cases are reported to the Centers for Disease Control and 
Prevention (CDC) [1], but recent studies have provided evidence that the true number of 
cases exceeds 300,000 each year [6, 7]. This figure represents a substantial disease 
burden, but the total economic burden to U.S. society is unknown [69].  
Existing economic evaluations for LD have limitations [69]. Most studies report 
direct medical costs, but lack data on productivity losses and non-medical costs [8, 10, 
80, 81]. Several studies were conducted two decades ago in a small number of 
Maryland counties where LD was emerging [10, 80, 86]; yet, this limited scope prevents 
generalizability to other endemic areas, and results may not be representative of today’s 
costs due to changes in disease management and healthcare structures. More recent 
studies have used diagnosis codes, e.g., International Classification of Diseases, Ninth 
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Revision, Clinical Modification (ICD-9-CM), to identify LD patients from insurance claims 
databases. However, the low sensitivity and specificity of these codes in identifying true 
cases [87, 88] may lead to incorrect estimates of direct medical costs attributable to LD. 
The few studies that provide more comprehensive cost estimates of LD were conducted 
in Europe under healthcare systems with financing structures different from the U.S. 
[83-85]. As such, updated estimates of the total societal cost of LD in endemic areas of 
the U.S., including direct and indirect costs, are needed [69]. 
We aimed to address current research gaps by conducting a prospective cost of 
illness study to estimate the economic burden of reported LD in high incidence areas of 
the U.S. The main objectives of this study were to estimate the total out-of-pocket costs 
incurred per patient and the total societal cost per patient due to LD. The secondary 
objective was to evaluate the association of selected disease and demographic factors 
with the total societal cost per patient. The results can be used by public health officials 
and communities to assess the cost-effectiveness of interventions to reduce the 
incidence of LD. 
Methods 
Study design 
This study was conducted as part of TickNET, a public health network of 
researchers who collaborate on tickborne disease research and surveillance [110]. We 
conducted a prospective, cost of illness study to estimate total costs incurred per patient 
due to LD in four high incidence states: Connecticut (CT), Maryland (MD), Minnesota 
(MN), and New York (NY). We used an incidence-based design, which measures the 
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cost of an illness from onset to resolution [76, 77]. Cost categories included direct costs 
(i.e., medical costs and related non-medical costs) and indirect costs (i.e., productivity 
losses). We used a patient perspective to estimate the total out-of-pocket cost incurred 
per patient, including medical costs, non-medical costs, and productivity losses. We 
used a societal perspective to estimate the total societal cost per patient, including total 
direct medical costs, non-medical costs, and productivity losses, regardless of who 
pays, whether the patient, third-party payer, or the government [74, 75].  
Study population 
The source population included pediatric and adult patients with clinician-
diagnosed LD reported to state and county public health surveillance authorities in CT 
and MN and in select counties in MD and NY (Appendix A, Table A.1). Eligible 
participants included those who met the national surveillance case definition for 
confirmed or probable LD during the study period [47]. For our study case definition, we 
used additional exclusion criteria to ensure enrollment of incident cases only. We 
excluded probable cases with no symptoms reported by the clinician, cases with a 
previous LD diagnosis within two calendar years of current diagnosis date, and cases 
with a diagnosis date > 12 months prior to date of enrollment. Non-English speaking 
participants were not enrolled due to limited resources for interpreters. 
Eligible patients were classified into three disease categories. Those with 
confirmed LD were divided into two groups: confirmed localized disease (i.e., those with 
EM rash) and confirmed disseminated disease (i.e., those with arthritis, lymphocytic 
meningitis, cranial neuritis or facial palsy, radiculoneuropathy, encephalomyelitis, 2nd or 
3rd degree heart block) [47]. The third category included probable cases with symptoms 
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reported by a clinician. To ensure enrollment of patients with a range of disease 
severity, we stratified recruitment by disease category and, using quota sampling, 
aimed to recruit approximately equal numbers of patients in each category each month. 
This strategy also allowed us to enroll patients as close to their diagnosis date as 
possible to reduce patient recall error regarding their costs. Each state aimed to enroll a 
minimum of 50 participants per disease category, with an overall minimum enrollment 
goal of 150 total participants per state. Recruitment and enrollment occurred September 
2014 through January 2016. 
Data collection 
Participants consented to data collection for either out-of-pocket costs and direct 
medical costs, or just the former. For out-of-pocket cost data, study coordinators 
conducted phone-based surveys with participants (or their legal guardians for pediatric 
participants) to collect age, gender, annual household income, insurance coverage, and 
LD onset date. Participants completed follow-up surveys at approximately one-month 
intervals using web-based or phone surveys [111]. Follow-up surveys ceased when 
participants reported no LD-related expenses for two consecutive surveys or when they 
completed the maximum of 12 surveys. The following were collected on all surveys: 
length of illness, symptoms, treatments, dates for LD-related healthcare visits, clinician 
contact information, out-of-pocket medical costs (prescription and non-prescription 
medicine, co-pays, medical bills), non-medical costs (roundtrip distance for healthcare 
visits; amount paid for assistance with self-care, dependent care, or house/yard 
maintenance due to LD), and productivity losses (amount of time taken off work or 
school due to LD symptoms or healthcare visits).    
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We collected direct medical costs for consenting participants by requesting billing 
codes (i.e., Current Procedural Terminology (CPT), 4th edition) directly from participants’ 
clinicians, as reported in surveys. Codes were requested for one month prior to the self-
reported disease onset date to the date of final survey. We used a date range instead of 
the individual visit dates reported by the participant in the event participants had 
incorrectly reported dates. The requested codes represented clinician visits, 
consultation and related in-office procedures, diagnostic testing, therapy, 
hospitalization, emergency department (ED) visits, or other procedures or relevant 
costs. Mean reimbursement for each CPT code collected for participants with private 
insurance was extracted from IBM® MarketScan® Research Databases, which include 
national medical claims data for privately insured persons up to age 65 and their 
dependents. Reimbursements for CPT codes collected for non-privately insured 
participants were extracted from the Physician Fee Schedule from the Centers for 
Medicare and Medicaid Services (CMS) [112]. Both MarketScan and CMS costs reflect 
reimbursements made for charges for medical procedures and services and include the 
amount paid by the insurer as well as the beneficiary (such as deductibles, copays, and 
coinsurance). The costs of reimbursements were extracted according to state, year, and 
inpatient vs outpatient status. 
Analysis 
In order to provide an overall weighted mean and median set of reimbursements 
and costs, disease category sampling probabilities were estimated from proportions 
derived from surveillance data [1] to approximate stratified random sampling. The 
inverse of the sampling probabilities was then used to weight the data for all analyses 
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described herein. Medical costs were adjusted to 2016 USD using the Consumer Price 
Index (CPI) for medical care, and nonmedical costs and productivity losses were 
adjusted using the general CPI [113]. We estimated the mean, median, 10th and 90th 
percentiles, and standard deviations of the patient out-of-pocket costs, direct medical 
costs, and total costs per patient. The Kruskall-Wallis rank sum test was used to 
evaluate differences in cost among the three disease categories (confirmed localized, 
confirmed disseminated, probable). Participants who did not complete three consecutive 
surveys were considered lost to follow-up and were excluded from all analyses.  
To estimate the out-of-pocket costs per patient, we summed self-reported 
medical costs, non-medical costs, cost of productivity losses, and other related costs 
over all surveys. To calculate the direct medical cost per patient, we summed the mean 
cost per CPT code collected for each patient. Further details for these calculations for 
out-of-pocket and direct medical costs are described in Section 1 of Appendix A. Finally, 
the total societal cost of LD per patient was calculated by summing the direct medical 
costs, self-reported non-medical costs, and the cost of lost productivity per patient.  
We conducted multivariable linear regression analysis using the weighted 
dataset to evaluate associations between total cost per patient and the following 
independent variables: disease category (confirmed localized, confirmed disseminated, 
probable), age group (< 18, 18 – 45, 46 – 65, > 65 years), gender (male, female), and 
state (CT, MD, MN, NY), controlling for insurance status (private or non-private 
insurance), income (< or ≥$60,000, which was the approximate median household 
income for participating states in 2015), and study year (2014, 2015, 2016). These 
potential confounders were identified a priori using directed acyclic graphs [114]. As is 
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typical for healthcare cost data, the distribution of total cost was highly skewed, resulting 
in heteroskedasticity of the residuals in the model [115]. Therefore, we transformed total 
cost per patient using natural logarithms and conducted sampling-weighted least 
squares regression. For interpretability, we exponentiated resulting regression 
coefficients and subtracted 1 to get the percent change in baseline cost for each 
independent variable of interest. The regression equation is given in Appendix A, 
Equation A1. 
Research approval was obtained from institutional review boards at CDC, 
Connecticut Department of Public Health, Maryland Department of Health, Minnesota 
Department of Health, New York State Department of Health, and Yale University. 
Extraction and calculation of mean cost per CPT code from IBM® MarketScan® 
Research Databases were conducted using SAS® 9.4; all other analyses were 
conducted using R version 3.5.2 [116-121]. 
Results 
During the enrollment period, 2,991 LD patients were identified and classified as 
confirmed cases or probable cases with symptoms reported (Figure 3.1). Of the 1,360 
(45%) reached, 1,118 (37%) consented to out-of-pocket cost surveys, with 901 (30%) 
participants with complete survey data included in the out-of-pocket cost analysis. 
Lastly, 613 (20%) participants had complete out-of-pocket and direct medical cost data 
and were included in the total cost analysis. 




Figure 3.1 Flowchart of study enrollment and completion by participants 
 
In weighted analysis, the study population included 402 (55%) confirmed 
localized, 238 (21%) confirmed disseminated, and 261 (24%) probable LD cases (Table 
3.1). Overall, 36% of participants were 46 – 65 years of age, 57% were male, and 94% 
were white. Most had income > $60,000 (71%) and private health insurance (70%). 
Appendix A, Table A.2 includes these results for the subset of our sample who 
completed out-of-pocket cost surveys and direct medical cost collection (n = 613). 









Disease category Confirmed localized 402 44.6 54.5 
 Confirmed disseminated 238 26.4 21.2 
 Probable 261 29.0 24.2 
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Age group 
(years) 
< 18 259 28.7 28.4 
18 – 45 145 16.1 16.1 
46 – 65 326 36.2 36.1 
> 65 171 19.0 19.4 
     
Gender Female 385 42.7 43.1 
Male 516 57.3 56.9 
     
Race Non-white 59 6.5 6.4 
 White 842 93.5 93.6 
     
State CT 225 25.0 23.7 
MD 239 26.5 26.8 
MN 268 29.7 29.6 
NY 169 18.8 20.0 
     
Income** ≤ $60,000 238 29.2 28.8 
> $60,000 576 70.8 71.2 
     
Insurance Private 632 70.1 70.2 
Other 269 29.9 29.8 
** Data were weighted according to disease category sampling probabilities derived from surveillance 
data. 
** Participants were not required to provide information on income; n = 814 
 
Participants reported a median of two provider visits and completed a median of 
three surveys (Table 3.2). Those with confirmed disseminated disease had the highest 
number of healthcare provider visits, reflecting the highest health care utilization, while 
those with probable disease had the highest number of surveys completed, reflecting 
the longest duration of costs incurred. Forty participants (4%) were still reporting 
symptoms and 25 (3%) were still incurring costs at survey 12, which is the maximum 
number of surveys before completion of the study. 















Median provider visits 
(range) 
 2 (1 – 47)   2 (1 – 25)  3 (1 – 45)  2 (1 – 47) 
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Median surveys  
(range) 
 3 (1 – 12)  2 (1 – 12)  3 (1 – 12) 4 (1 – 12) 
 
Overall, the total out-of-pocket cost per patient ranged from $0.46 to $30,628. 
The median cost was $244, and the mean cost was $1,242, reflecting a highly positively 
skewed distribution (Table 3.3). Participants with confirmed disseminated LD had the 
highest median and mean cost ($358 and $1,692, respectively), followed by those with 
probable disease ($315 and $1,277, respectively), then confirmed localized disease 
($170 and $1,070).  
Table 3.3 Out-of-pocket cost of LD per patient, by disease category 











All  901 244 1,252 2,972 29 3,139 0 – 30,628 
Confirmed 
localized  
402 170 1,070 4,164 27 2,535 1 – 26,686 
Confirmed 
disseminated  
238 358 1,692 7,323 32 4,116 2 – 30,628 
Probable  261 315 1,277 4,629 34 3,987 0 – 18,833 
* The estimates for the overall population use the sample-weighted data except the range. 
 
Figure 3.2 shows the median and mean cost per component of the total out-of-
pocket cost by disease category (see Appendix A, Table A.3 for values). For all disease 
categories, productivity losses had the highest mean cost of all cost components, at 
$727 for those with confirmed disseminated disease, $627 for those with probable 
disease, and $540 for those with confirmed localized disease. However, the median 
cost of productivity losses for all disease categories was $0. Medical bills had the next 
highest cost, with a median of $83 and a mean of $628 for those with confirmed 
disseminated disease, a median of $83 and a mean of $389 for those with probable 
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disease, and a median of $42 and a mean of $314 for those with confirmed localized 
disease. All other cost components for all disease categories had median costs < $25 
and mean costs < $80. 
 
Figure 3.2 Mean and median out-of-pocket Lyme disease costs per patient, by 
disease and cost category 
* The gray bars indicate mean cost, and the black lines indicate median cost. 
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Nearly 10,000 CPT codes were collected to estimate direct medical costs (n = 
9,679). The most common codes were for office visits (17%) and routine venipuncture 
(6%) (Appendix A, Table A.5). Overall, the direct medical cost of LD per patient ranged 
from $50 to $121,869, with a median of $478 and mean of $1,333 (Table 3.4). 
Participants with confirmed disseminated LD had the highest median and mean direct 
medical cost ($696 and $2,537, respectively), followed by those with probable disease 
($612 and $1,804, respectively), then confirmed localized disease ($374 and $668, 
respectively).  
Table 3.4 Direct medical cost of LD per patient, by disease category  











All  613 478 1,333 5,690 164 1,932 50 – 121,869 
Confirmed 
localized  
273 374 668 1,715 136 1,224 50 – 13,050 
Confirmed 
disseminated  
154 696 2,537 20,220 259 4,366 147 – 121,869 
Probable  186 612 1,804 15,188 237 2,454 124 – 105,494 
* Excludes CPT codes deemed unrelated to LD per physician subject matter expert; see Appendix A for 




Overall, the total cost of LD per patient ranged from $54 to $122,766; the median 
was $690 and the mean was $2,032 (Table 3.5). Participants with confirmed 
disseminated LD had the highest median and mean total cost ($1,081 and $3,251, 
respectively), followed by those with probable disease ($940 and $2,620, respectively), 
then confirmed localized disease ($493 and $1,307, respectively). Appendix A, Table 
A.6 includes mean and median total costs per patient by demographic characteristic. 
Applying these per patient total costs to the total number of LD cases in the U.S. results 
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in an approximate aggregate cost to U.S. society of $800 million annually (Appendix A, 
Section A.2 and Table A.8). 
 
Table 3.5 Total cost of LD per patient, by disease category 











All  613 690 2,032 6,091 203 4,201 54 – 122,766 
Confirmed 
localized  
273 493 1,307 3,559 154 2,678 54 – 18,322 
Confirmed 
disseminated  
154 1,081 3,251 20,908 297 6,238 216 – 122,766 
Probable  186 940 2,620 15,533 316 5,021 130 – 105,500 
* Total cost includes patient out-of-pocket nonmedical costs, productivity losses, and direct medical costs. 
The estimates for the overall population use the sample-weighted data except the range. 
 
In multivariable linear regression analysis, disease category, age, and state were 
associated with total cost per patient (Table 3.6; Appendix A, Table A.6). Participants 
with confirmed disseminated disease and probable disease had costs that were 120% 
and 59% higher, respectively, than those with confirmed localized disease (p < 0.001). 
Participants aged 18 – 45 and 46 – 65 years had costs that were 96% and 108% higher, 
respectively, than those aged < 18 years (p < 0.001); however, those aged > 65 years 
did not have significantly different costs. MN residents had 75% higher costs than CT 
residents, but MD and NY residents did not have significantly different costs than CT 
residents.  
 
Table 3.6 Impact* on total cost of LD per patient due to disease category, age 







95% CI for total 
cost difference 
(2016 USD) 
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Baseline cost** NA 305 206 – 451  
    
Variable    
LD category    
 Confirmed, localized (reference)    
 Confirmed, disseminated 120 367 188 – 545  
 Probable 59 181 71 – 291  
Age group (years)    
 < 18 (reference)    
 18 – 45  96 293 107 – 479  
 46 – 65  108 331 175 – 486  
 > 65  27 84 -28 – 195  
Gender    
 Female (reference)    
 Male 11 35 -26 – 95  
State    
 CT (ref)    
 MD 0 0 -76 – 76  
 MN 75 229 114 – 345  
 NY -6 -19 -119 – 82  
* Results from sample-weighted multivariable linear regression analysis. See Appendix A, Equation A.1 
and Table A.7 for more model results. 
*The model included independent variables of interest, i.e., disease category, age group, gender, and 
state, while controlling for insurance status, income, and study year. Adjusted R2 = 0.19. Baseline cost 
represents a patient with confirmed localized LD, female, aged < 18 years, with residence in CT, without 
private insurance, with income < $60,000, and study year of 2014. 
 
Discussion 
We found patients had an average out-of-pocket cost of approximately $1,200 
(median cost ≈ $240) and an average total cost of approximately $2,000 (median cost ≈ 
$700). In stratified analyses by disease category, those with confirmed disseminated 
and probable disease had approximately double or more the total cost per patient 
compared to those with confirmed localized disease, highlighting the importance of early 
and accurate diagnosis. Having disseminated or probable disease, being aged 18 – 65 
years, and having residence in MN had the greatest impact on the total cost of LD. 
While median total costs are typically $1,000 or less for all disease categories, average 
costs are substantially higher, indicating that most patients have low costs, but some 
experience very high costs related to LD. Similarly, the low median number of provider 
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visits and hours of lost productivity suggest that illness with LD is manageable for most, 
but for a minority, it may be highly disruptive. With over 300,000 cases of LD each year, 
these costs represent a significant economic burden to U.S. society and underscore the 
need for effective prevention methods. 
Classification of a reported case as probable means a clinician has diagnosed 
LD in a patient and there is laboratory evidence of infection. However, any reported 
symptoms are typically non-specific and do not meet clinical criteria for a confirmed 
case (i.e., EM, arthritis, carditis, or neurologic manifestations) [47]. Further, laboratory 
evidence of infection includes single-tier IgG immunoblot seropositivity, which might 
indicate past, rather than current, infection. As such, the increased costs for probable 
cases might result from higher healthcare utilization for disease unrelated to LD. 
In a geographically-limited study of LD patients residing on the eastern shore of 
MD in 1998 – 2001, Zhang et al. reported mean and median total costs of $3,494 and 
$500 (2016 USD) per patient, respectively, attributable to LD [10]. However, their case 
definition differed from ours with inclusion of patients with early, late, and suspected 
disease, as well as those with tick bite and other related complaints, as identified using 
diagnosis codes in medical records. They reported mean and median total costs of 
$2,275 and $689 (2016 USD), respectively, for patients with clinically defined early 
disease, which are higher than what we found for confirmed, localized disease ($1,307 
and $493, respectively). In regression analyses, Zhang et al. found that disease 
category and age, but not gender, were significantly associated with direct medical 
costs, similar to our findings for total cost. In another U.S. study using nationwide 
commercial insurance claims data to compare cases with matched controls in 2006 – 
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2010, Adrion et al. estimated an increase of $3,009 (2016 USD) in direct medical costs 
attributable to LD over a 12-month period [8]. This cost is higher than our overall mean 
direct medical cost ($1,333), likely due to study population differences, but it is similar to 
that found for our confirmed disseminated patients ($2,537). In a recent study in the 
Netherlands, Van den Wijngaard, et al. used a societal perspective to estimate a total 
cost of $137 for patients with EM only and $6,398 (2016 USD) for those with 
disseminated Lyme borreliosis [85]. These costs are lower and higher, respectively, 
compared to our results for confirmed localized ($1,307) and confirmed disseminated 
($3,251) disease. These cost differences may result from different healthcare financing 
systems in the U.S. versus Europe or from variations in clinical manifestations resulting 
from infection with different B. burgdorferi sensu lato strains in the two continents [83-
85]. 
 This study has several strengths. Our study adds to the scarce literature on the 
economic burden of LD and provides a comprehensive estimate of the cost of LD, both 
to the patient and to society as a whole. Prospective collection of all patient out-of-
pocket costs, including productivity losses, has not been done in previous studies. 
Further, these results provide estimates of the cost savings per LD case averted, which 
can be used in cost-benefit analyses of prevention interventions, such as a potential 
vaccine. Lastly, our regression results underscore that targeted messaging regarding 
increased awareness of disease risk and early diagnosis may aid in preventing 
disseminated disease and its associated high cost. 
This study is also subject to several limitations. Our estimates may be affected by 
recall error, either by patients or providers, though we attempted to mitigate such error 
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by enrolling patients as close to disease onset as possible, by surveying them monthly 
to capture ongoing costs, and by requesting codes from providers for a date range 
instead of for individual visits. However, by requesting codes over a date range, some 
billing codes unrelated to LD (e.g., for other comorbidities) may have been included 
despite our excluding codes definitively unrelated to LD, potentially leading to 
overestimates. Information bias may have occurred in our measure of association 
between disease category and cost because those with milder disease may be more 
likely to forget some costs compared to those with more severe disease, with a potential 
bias away from null. Additionally, while the use of quota sampling to recruit reported 
cases was necessary to enroll patients near disease onset, this non-probability 
sampling method limits our ability to meet assumptions for calculating sampling error. 
Use of surveillance data to weight responses by disease category was intended to 
ensure representativeness by disease category. Nevertheless, in surveillance data, the 
number of confirmed localized cases are likely underreported and confirmed 
disseminated cases are likely overreported, so our overall cost may be overestimated 
[32, 122]. Finally, this study did not include costs related to mortality from LD, as no 
enrolled participants died. While very rare, mortality from Lyme carditis has been 
reported [108, 109], and these costs would greatly increase estimates of productivity 
losses. 
While not necessarily a limitation, the generalizability of our results is limited to 
reported cases of LD in high incidence states [47]. These estimates may not represent 
the cost of diagnosed but unreported LD, and these estimates do include costs for 
suspected LD (e.g., consultation for tick bite, negative diagnostic tests), undiagnosed 
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LD, or non-acute LD (e.g., patients with post-treatment LD syndrome). These costs 
further increase the total economic burden attributable to LD and should be evaluated in 
future studies. Our estimates are likely generalizable to high incidence states in the 
northeastern, mid-Atlantic, and upper midwestern states, but may not reflect costs in 
states with emerging or low incidence LD. 
In conclusion, LD represents a significant economic burden to individual patients 
and U.S. society. The aggregate cost of diagnosed LD could be upwards of $800 million 
annually, not including suspected, undiagnosed, or non-acute LD. These findings 
emphasize the importance of early and accurate diagnosis to reduce morbidity and 
associated costs. Future efforts should include cost-effectiveness analyses of current 
and future prevention methods, such as a vaccine, in addition to economic evaluations 
of unreported, suspected, and non-acute LD.  
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CHAPTER 4: EVALUATING PUBLIC ACCEPTABILITY OF A POTENTIAL LYME 
DISEASE VACCINE USING A POPULATION-BASED, CROSS-SECTIONAL SURVEY 






Lyme disease (LD) incidence is increasing, despite current prevention options. New LD 
vaccine candidates are in development that have the potential to substantially reduce 
disease incidence; however, investigation of the acceptability of a LD vaccine among 
potential consumers is needed prior to any vaccine coming to market. We conducted a 
population-based, cross-sectional study to estimate willingness to receive a potential LD 
vaccine and factors associated with willingness. 
Methods 
The web-based survey was administered to a random sample of Connecticut, Maryland, 
Minnesota, and New York residents June – July, 2018. Survey-weighted descriptive 
statistics were conducted to estimate the proportion willing to receive a LD vaccine. 
Multivariable, multinomial logistic regression models were used to quantify the 
association of sociodemographic characteristics and LD vaccine attitudes with 
willingness to receive a LD vaccine. 
Results  
The survey response rate was 6.3% (n = 3,313). We estimated that 64% of residents 
were willing to receive a LD vaccine, while 30% were uncertain and 7% were not willing. 
Those who were uncertain were more likely to be parents, adults 45 – 65 years of age, 
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non-white, have less than a bachelor’s degree, or have safety concerns about a 
potential LD vaccine compared to those who were willing. Those who were unwilling 
were also more likely to be non-white, have less than a bachelor’s degree, or have 
safety concerns about a potential LD vaccine, but they also would not be influenced by 
a positive recommendation from a HCP, have low confidence in vaccines in general, 
and have low perceived risk of contracting LD compared to those who were willing. 
Discussion 
Overall, willingness to receive a potential LD vaccine was high. Effective communication 
by clinicians regarding safety and other vaccine parameters to those groups who are 
uncertain about LD vaccination will be critical for increasing vaccine uptake and 
reducing LD incidence.  
  




Lyme disease (LD) is a multi-system illness caused by infection with Borrelia 
burgdorferi. These  bacteria are transmitted to humans and animals by the bite of 
infected Ixodes scapularis ticks in northeastern, mid-Atlantic, and upper-midwestern 
regions of the United States (US)[1, 2]. Early symptoms of LD most often include a 
characteristic bull’s-eye rash known as erythema migrans, as well as flu-like symptoms 
[29]. If left untreated, the disease can disseminate and lead to more severe 
manifestations, such as arthritis, meningitis, or carditis, the last of which can be fatal in 
rare cases. Most patients will experience a full recovery after antibiotic treatment, 
although a small proportion (~ 10%) may continue to experience symptoms related to 
disease sequelae [29, 37, 60, 123, 124].  
In the US, there is a bimodal peak in LD incidence by age group, highest among 
children aged 5 – 10 years and adults aged 45 – 55 years, with a slight male 
predominance in most age groups [1]. Incidence has been increasing, with over 30,000 
cases reported annually to the Centers for Disease Control and Prevention in the last 
decade [1]. However, recent studies have provided evidence that cases may be 10 – 12 
fold underreported, with the true number estimated at over 300,000 annually [6, 7].  
A safe and efficacious vaccine for LD called LYMErix was available for persons 
aged 15 – 70 years from 1998 until 2002 in the US [18, 19]. This vaccine conferred 
protection based on a recombinant outer surface protein A (rOspA) of B. burgdorferi.  In 
2002, it was voluntarily discontinued by the manufacturer, reportedly due to poor sales 
[20]. However, several factors have been highlighted as reasons contributing to low 
demand. Most importantly, it was not available for children under 15 years, one of the 
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highest risk age groups. Further, some have cited tepid and cumbersome 
recommendations by the Advisory Committee on Immunization Practices (ACIP) as a 
potential reason for low demand by clinicians and the public [17, 57]. Vocal opposition 
by some Lyme disease patient advocacy groups, based on unsubstantiated claims that 
the vaccine caused Lyme arthritis, is also thought to have played a role in LYMErix’s 
withdrawal [50, 53-55]. The introduction and withdrawal of LYMErix also inauspiciously 
coincided with the then nascent anti-vaccination movement [55]. Since its withdrawal, 
the number of LD cases reported annually has nearly doubled, despite available 
personal and yard-based prevention methods [21, 48]. The inability of current measures 
to stem rising case numbers highlights the need for a prevention modality suitable for 
use at the population level, namely, a LD vaccine [125]. 
After nearly two decades without an effective prevention method, new LD 
vaccine candidates are in development, with initial results showing favorable safety and 
immunogenicity profiles and potential availability by 2024 [66-68]. While rising LD 
incidence would ostensibly result in increased demand for a vaccine, the controversial 
climate surrounding LD [45] and general vaccine hesitancy among some groups [70-73] 
necessitate further investigation of the acceptability of a LD vaccine among potential 
consumers prior to any vaccine coming to market. The primary objective of this study 
was to estimate what proportion of people living in states with a high incidence of LD 
would be willing to receive a vaccine that protects against LD if one were available. The 
secondary objective was to evaluate factors associated with willingness to receive a LD 
vaccine.  




Study design and sampling 
In the summer of 2018, we conducted a population-based, cross-sectional survey 
using address-based sampling of persons living in four states with high incidence of LD 
[126]. The target population included all residents of Connecticut, Maryland, Minnesota, 
and New York, excluding New York City. The sampling frame included all households 
with residential addresses listed in the U.S. Postal Service (USPS) database in these 
areas. We used a stratified, two-stage sampling design where the strata were counties 
from the above-mentioned states. The primary sampling unit was the household, while 
the unit of observation was the individual, with a single individual selected within the 
household. Addresses were purchased from a marketing company that receives 
updated information on a monthly basis directly from USPS based on change of 
address submissions. Household addresses were stratified according to county, and the 
number of addresses selected per county was allocated proportional to county 
population size.  Households were randomly selected within counties.  An individual 
within the household was selected as the one who had the most recent birthday, 
regardless of age, an established technique to approximate random sampling [127]. For 
minors selected, parents or guardians provided responses. Responses to the survey 
were made by individuals ≥ 18 years of age. Subsequently, the term “respondent” will 
refer to those about whom information was collected. 
To estimate the proportion of residents willing to receive a potential LD vaccine, 
the sample size calculation parameters included a conservative estimate of 50% of 
participants responding “Yes” for willingness to receive a LD vaccine; α = 0.01; an 
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acceptable margin of error of +/- 5%; and 2 clusters for multi-stage sampling [128]. 
These parameters resulted in a required sample size of 665 respondents per state 
(2,660 respondents total). Based on a 2016 survey using address-based sampling in 
Connecticut and Maryland [100], we anticipated a 5% response rate and, therefore, 
recruited 13,300 individuals per state (53,200 total) to obtain a sample representative of 
the populations in these states (including responses for both adults and children), in the 
absence of non-response. 
Data collection 
Recruitment, enrollment, and survey completion occurred during June – July 
2018, with data collection corresponding with peak tickborne disease activity in these 
states. The survey invitation postcard was mailed to each randomly selected household; 
it summarized the study and explained which household resident should complete the 
survey (based on the most recent birthday) in English. The postcard also provided a 
web link, quick response (QR) barcode, and a unique access code to complete the 
online survey; alternatively, respondents could choose to complete the survey over the 
phone with study coordinators. A reminder was mailed two weeks following the original 
mailing, and the online surveys were open for approximately four weeks.  
The following sociodemographic variables were collected from survey responses: 
age of the person about whom information was collected; age of the parent or guardian 
responding for the minor participant, if applicable; gender of the person about whom 
information was collected; gender of the parent or guardian responding for the minor 
participant, if applicable; race and ethnicity of the respondent; education of the 
respondent; number of adult household members; and number of minor household 
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members. An additional variable for metropolitan status (large central metropolitan area 
vs other) by county was created using the urban-rural classification scheme from the 
National Center for Health Statistics [129]. The main outcome variable was whether the 
respondent would be willing to receive a LD vaccine if one were available (or vaccinate 
the minor, if a parent respondent); the response options were “Yes”, “No”, and “Don’t 
know.” The following covariates were also collected from survey responses: how much 
LD vaccine safety concerns affect willingness to be vaccinated; how much cost affects 
willingness to be vaccinated; how much a positive recommendation for the LD vaccine 
from a healthcare provider (HCP) affects willingness to be vaccinated; history of LD 
diagnosis among household members; level of concern about getting LD; time spent in 
tick habitat; whether vaccines, in general, benefit people; primary source for LD 
information; and primary location for receiving vaccinations. Survey questions and 
response options are listed in Appendix B, Table B.1. 
Analysis 
The data were weighted to account for the unequal selection probabilities per 
respondent for the two-stage sampling design [127, 130]. We compared the sample 
distributions of age and gender to known population totals using chi-squared goodness-
of-fit tests, and as necessary, conducted post-stratification according to county 
population distributions of age and gender to reduce sampling error and nonresponse 
error [130-133]. All analyses were conducted using the weighted, post-stratified dataset, 
and all analyses incorporated the sampling design into standard error and confidence 
interval computation and statements of inference.  
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To estimate what proportion of people in Connecticut, Maryland, Minnesota, and 
New York would be willing to receive a vaccine that protects against LD if one were 
available, summary statistics were computed for the three-level response for willingness 
to receive a vaccine. Additionally, descriptive analyses were conducted for the following 
independent variables: sociodemographic characteristics; LD history, attitudes, and 
practices; vaccine attitudes; primary sources of LD information; and primary location for 
receiving vaccines.  
To evaluate factors associated with willingness to receive a LD vaccine, we 
stratified the outcome by the above mentioned independent variables, and Pearson chi-
squared tests with Rao and Scott design-based adjustments were used to evaluate 
differences in the outcome across levels of each independent variable [134].  Because 
our outcome of willingness to be vaccinated has three, unordered levels, multinomial 
multivariable logistic regression models were used to quantify the association between 
LD vaccination responses and independent variables of interest. For each model, we 
used “Yes” responses to willingness to receive a vaccine as the reference group to 
which “No” and “Don’t know” responses were compared. The independent variables of 
interest included sociodemographic characteristics (i.e., gender, age category, state, 
race, and education), LD vaccine safety concerns, LD vaccine cost concerns, and 
positive recommendation for the LD vaccine from an HCP. The last three independent 
variables were dichotomized for analysis (Yes = “Some” or “A lot”; No = “Not at all” or 
“Don’t know”). Separate models were built for each independent variable of interest with 
a specific set of potential confounders identified a priori (Appendix B, Table B.2), and 
model diagnostics were conducted for each model fit. Multinomial logistic regression 
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model results are presented as unadjusted and adjusted odds ratios (ORs) and 95% 
confidence intervals (CIs).  
Additionally, we conducted a sensitivity analysis to evaluate whether the odds 
ratios approximately estimated prevalence ratios (PRs). We conducted standard 
multivariable logistic regression by sub-setting the dataset first to “Yes” and “No” 
responses to willingness to be vaccinated and then “Yes” and “Don’t know” responses, 
using “Yes” as the reference level for each model and the same set of independent 
variables as the multinomial logistic regression models described above. We then 
compared resultant adjusted ORs and adjusted PRs (Appendix B, Table B.5).  
We evaluated non-random missingness in our outcome variable related to non-
response (i.e., selection bias) using Heckman-type selection models, also called 
generalized Tobit models [135-137]. Heckman models use two steps to first model the 
selection process using one or more independent selection variables and then the 
outcome equation (i.e., the regression equation for the outcome of interest). Results of 
the two-step process indicate whether selection bias is present based on the coefficient 
of the inverse Mill’s ratio; if so, a correction factor incorporating the coefficient of the 
inverse Mill’s ratio is applied to results. 
 Survey development, administration, data collection, and data management were 
conducted using the Research Electronic Data Capture (REDCap) software hosted at 
Yale University [138, 139]. R version 3.5.2 [116-121] was used for all analyses. This 
study was conducted through TickNET, a public health network composed of 
researchers at state health departments, universities, and the Centers for Disease 
Control and Prevention (CDC) who collaborate on tickborne disease research and 
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surveillance [110]. Research approval and waiver of documentation of informed consent 
were obtained from institutional review boards at CDC, Connecticut Department of 
Public Health, Maryland Department of Health, Minnesota Department of Health, New 
York State Department of Health, and Yale University. Respondents’ participation in the 
survey indicated consent.  
Results 
 The survey response rate was 6.3% (n = 3,313). Fifty-nine records were ineligible 
due to missing age data (n=38), the respondent not being the person in the household 
with the last birthday (n = 15), the adult respondent not being the one to make 
vaccination decisions for the selected minor (n = 1),  or the respondent not answering 
the main outcome question regarding willingness to receive a LD vaccine (n = 5). An 
additional 48 records with missing gender information were removed prior to analysis 
because gender information was necessary for post-stratification. The resulting sample 
available for analysis was 3,206 records. The coefficient of the inverse Mill’s ratio 
resulting from Heckman selection models indicated no evidence of significant selection 
bias (Appendix B, Table B.4). 
Individuals in the sample were older with a higher proportion female compared to 
the source population; therefore, we post-stratified the data on age and gender as 
described above [130-133]. The following proportions of demographic characteristics 
were fixed by post-stratification: 54% of residents were female, 17% were aged ≥ 65 
years, 33% were from New York, and 28% lived in a large central metropolitan area 
(Table 4.1). In weighted analysis, we estimated that 15% of residents were parents, 
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85% were white, and 65% had a bachelor’s degree or higher (For brevity, CIs are 
reported in Table 4.1.).  
 For our outcome of interest, we estimated that 64% (n = 2098) of residents were 
willing to receive a LD vaccine, while 7% (n = 190) were not willing and 30% (n = 918) 
were uncertain (Table 4.1). Regarding LD history, attitudes, and practices, we estimated 
that 18% of residents experienced a past LD diagnosis in their household, and 86% 
expressed concern about a future LD diagnosis. An estimated 71% of residents spent 
time in tick habitat at least weekly. Nearly all residents (92%) used some type of LD 
prevention measure, while 70% were confident that available measures can prevent LD. 
The vast majority (94%) were confident that recommended vaccines benefit people. 
Regarding LD vaccine attitudes, the majority of residents had concerns about vaccine 
safety (71%) and cost (63%), and the majority (89%) indicated that a positive 
recommendation from an HCP for the LD vaccine would influence their willingness to be 
vaccinated. In stratified analyses, differences in willingness to be vaccinated were 
observed for all characteristics and were significant at α = 0.05.  
Table 4.1 Study population characteristics and willingness to receive a potential 
LD vaccine, weighted % (95% confidence interval) 
  Willingness to receive a LD vaccine* 
Characteristic All** Yes No Don’t Know 
Total, N = 3206  
64 (62, 65) 
n = 2098 
7 (6, 8) 
n = 190 
30 (29, 31) 
n = 918 
Demographics     
Gender***     
Female 54 54 (53, 54) 64 (59, 70) 54 (52, 56) 
Male 46 46 (46, 47) 36 (30, 41) 46 (44, 48) 
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Age category*** (years)     
< 18 15 14 (13, 15) 13 (10, 16) 19 (17, 20) 
18-44 33 36 (35, 37) 34 (29, 40) 28 (26, 30) 
45-64 34 32 (31, 33) 39 (33, 45) 38 (36, 40) 
65+ 17 18 (18, 19) 14 (11, 17) 16 (14, 17) 
State     
CT 20 21 (21, 22) 17 (12, 21) 16 (15, 18) 
MD 27 27 (26, 28) 24 (19, 29) 29 (27, 31) 
MN 20 20 (19, 21) 24 (20, 28) 18 (17, 20) 
NY 33 32 (31, 33) 35 (29, 41) 37 (35, 39) 
Race     
White 85 (84, 86) 87 (86, 88) 75 (69, 81) 81 (79, 83) 
Non-white 15 (14, 16) 13 (12, 14) 25 (19, 31) 19 (17, 21) 
Education     
Some college or less 35 (33, 36) 31 (29, 32) 50 (44, 56) 39 (37, 41) 
Bachelor’s degree or higher 65 (64, 67) 69 (68, 71) 50 (44, 56) 61 (59, 63) 
Metropolitan status     
Large central metro area 28 28 (27, 29) 38 (33, 44) 26 (24, 28) 
Other 72 72 (71, 73) 62 (56, 67) 74 (72, 76) 
LD history, attitudes, and practices     
Past LD diagnosis in household     
Yes 18 (17, 19) 21 (20, 22) 14 (9, 19) 13 (12, 15) 
No 82 (81, 83) 79 (78, 80) 86 (81, 91) 87 (85, 88) 
Concern about future LD diagnosis     
Yes 86 (85, 86) 94 (93, 95) 56 (50, 62) 74 (72, 76) 
No 14 (14, 15) 6 (5, 7) 44 (38, 50) 26 (24, 28) 
Time spent in tick habitat     
At least weekly 71 (70, 73) 82 (80, 83) 51 (45, 57) 54 (52, 56) 
Monthly or less 29 (27, 30) 18 (17, 20) 49 (43, 55) 46 (44, 48) 
Current use of LD prevention 
measures     
Yes 92 (91, 93) 94 (93, 95) 87 (83, 91) 90 (88, 91) 
No  8 (7, 9) 6 (5, 7) 13 (9, 17) 10 (9, 12) 
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Confidence in LD prevention 
measures     
Yes 70 (68, 71) 67 (65, 68) 81 (76, 85) 74 (71, 76) 
No 30 (29, 32) 33 (32, 35) 19 (15, 24) 26 (24, 29) 
Confidence in general vaccines     
Yes 94 (93, 95) 98 (97, 98) 69 (64, 74) 91 (89, 93) 
No 6 (5, 7) 2 (2, 3) 31 (26, 36) 9 (7, 11) 
LD vaccine attitudes     
LD vaccine safety concerns     
Yes 71 (70, 72) 68 (66, 69) 80 (75, 84) 75 (74, 77) 
No 29 (28, 30) 32 (31, 34) 20 (16, 25) 25 (23, 26) 
HCP influence on LD vaccination     
Yes 89 (88, 89) 93 (92, 94) 57 (52, 63) 87 (85, 89) 
No 11 (11, 12) 7 (6, 8) 43 (37, 48) 13 (11, 15) 
LD vaccine cost concerns     
Yes 63 (62, 65) 66 (65, 68) 34 (28, 40) 64 (62, 67) 
No 37 (35, 38) 34 (32, 35) 66 (60, 72) 36 (33, 38) 
*All comparisons made in stratified analyses using Pearson chi-squared tests with Rao and Scott design-
based adjustments had resultant p values ≤ 0.001. 
* *County distributions of gender and age were used for post-stratification; as such, these point estimates 
for the overall sample are fixed at the population values and have no associated interval estimate. 
Because state and metropolitan status are based on county population totals, these point estimates are 
also fixed. 
***Gender and age categories represent the potential vaccinee, i.e., adult respondents and the children for 
whom parents responded. 
 
Overall, we estimated that the top sources of LD information for residents were 
health websites (29%, 95% CI: 28%, 30%), search engines (22%, 95% CI: 21%, 23%), 
and HCPs (21%, 95% CI: 20%, 22%) (Figure 4.1), with similar proportions for those who 
said “Yes” and “Don’t know” to potential LD vaccination (Appendix B, Figure B.1). 
Among those who said “No” to potential LD vaccination, a lower proportion (22%, 95% 
CI: 17%, 27%) cited health websites as a primary source of LD, and a higher proportion 
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cited search engines (25%, 95% CI: 19%, 31%) and social media (6%, 95% CI: 2%, 
9%), compared to residents overall and those who said “Yes” and “Don’t know” to LD 
vaccination (Appendix B, Figure B.1).  
 
 
Figure 4.1 Residents’ primary source for LD information, weighted % and 95% 
confidence intervals* 
*95% confidence interval are shown in the black bars. 
 
Overall, the top three locations for receiving vaccinations were HCP offices, 
clinics, or hospitals (82%, 95% CI: 81%, 83%); pharmacies (12%, 95% CI: 11%, 12%); 
and workplaces (3%, 95% CI: 2%, 3%) (Figure 4.2). Proportions were similar for those 
who said “Yes” and “Don’t know” to potential LD vaccination, while a higher proportion 
of those who said “No” reported they “do not get vaccines” (14%, 95% CI: 10%, 18%) or 
that they “Don’t know” their primary location for receiving vaccination (5%, 95% CI: 4%, 
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6%), compared to residents overall and those who said “Yes” and “Don’t know” to LD 
vaccination (Appendix B, Figure B.2). 
 
Figure 4.2 Residents’ primary location for receiving vaccination, weighted % and 
95% confidence intervals 
*95% confidence interval are shown in the black bars. 
 
  
Table 4.2 shows the estimated unadjusted and adjusted ORs and 95% CIs 
resulting from survey-weighted, multivariable, multinomial logistic regression analysis. In 
terms of sociodemographic characteristics, the odds of parents of minors responding 
“Don’t know” (vs. “Yes”) to LD vaccination was 1.6 times that of the reference group, 
those 65 years and older (OR: 1.60, 95% CI: 1.06, 2.42). The odds of those aged 45 – 
64 years responding “Don’t know” were also higher compared to those 65 years and 
older (OR: 1.40, 95% CI: 1.07, 1.85). Females had only slightly higher odds of 
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responding “No” (vs. “Yes”) to LD vaccination compared to males (OR: 1.55, 95% CI: 
0.90, 2.68) and did not have higher odds of responding “Don’t know”. Those in Maryland 
and New York had higher odds of responding “Don’t know” to LD vaccination compared 
to those in Connecticut (aOR: 1.42, 95% CI: 1.01, 1.99 and aOR: 1.52, 95% CI: 1.05, 
2.19, respectively). No differences were found among states for “No” responses. Non-
white residents had higher odds of responding “No” to LD vaccination (aOR: 2.29, 95% 
CI: 1.21, 4.32) and “Don’t know” (aOR: 1.54, 95% CI: 1.10, 2.17) compared to white 
residents.  Those with less than a bachelor’s degree had higher odds of responding 
“No” (aOR: 2.21, 95% CI: 1.28, 3.83) and “Don’t know” (aOR: 1.47, 95% CI: 1.13, 1.91) 
to LD vaccination compared to those with more education.  
In terms of attitudes toward a LD vaccine, those with safety concerns had higher 
odds of responding “No” and “Don’t know” to LD vaccination (aOR: 2.62, 95% CI: 1.49, 
4.6; aOR: 1.99, 95% CI: 1.42, 2.78, respectively) compared to those without safety 
concerns. Those who said HCP recommendation would not influence their willingness 
to be vaccinated had much higher odds of responding “No” (aOR: 5.21, 95% CI: 2.72, 
10.00) but only slightly higher odds of responding “Don’t know” (aOR: 1.42, 95% CI: 
0.94, 2.15). Finally, those with LD vaccine cost concerns had lower odds of responding 
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Table 4.2 Unadjusted and adjusted odds ratios for LD vaccination responses using multinomial logistic 
regression 
  LD vaccination responses (ref. = Yes) 
   
  No  Don’t Know 
Variable  OR (95% CI) aOR (95% CI)  OR (95% CI) aOR (95% CI) 
       
Vaccinee age category*  
(ref. = 65 + years) 
   
 
  
 <18  1.19 (0.38, 3.68) NA  1.60 (1.06, 2.42) NA 
 18 – 44  1.23 (0.69, 2.19) NA  0.91 (0.66, 1.26) NA 
 45 – 64  1.59 (0.88, 2.85) NA  1.40 (1.07, 1.85) NA 
Gender*  
(ref. = Male) 
      
 Female   1.55 (0.90, 2.68) NA  1.00 (0.77, 1.31) NA 
State1  
(ref. = Connecticut) 
      
 Maryland  1.13 (0.60, 2.13) 1.16 (0.61, 2.19)  1.40 (0.99, 1.98) 1.42 (1.01, 1.99) 
 Minnesota  1.54 (0.77, 3.07) 1.51 (0.76, 3.00)  1.20 (0.83, 1.73) 1.19 (0.82, 1.73) 
 New York   1.41 (0.79, 2.50) 1.41 (0.80, 2.48)  1.52 (1.05, 2.20) 1.52 (1.05, 2.19) 
Race2  
(ref. = White) 
      
 Non-white   2.24 (1.18, 4.26) 2.29 (1.21, 4.32)  1.55 (1.10, 2.18) 1.54 (1.10, 2.17) 
Education3 
(ref. =  ≥ Bachelor’s degree) 
      
 < Bachelor's degree  2.29 (1.35, 3.88) 2.21 (1.28, 3.83)  1.45 (1.12, 1.87) 1.47 (1.13, 1.91) 
LD vaccine safety 
concerns4  
(ref. = No) 
      
 Yes  1.86 (1.12, 3.1) 2.62 (1.49, 4.60)  1.48 (1.07, 2.03) 1.99 (1.42, 2.78) 
HCP influence on LD 
vaccination5 
 (ref. = Yes) 
      




 1.92 (1.30, 2.84) 1.42 (0.94, 2.15) 
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LD vaccine cost concerns6  
(ref. = No) 
      
 Yes  0.26 (0.16, 0.43) 0.36 (0.20, 0.64)  0.92 (0.74, 1.16) 1.07 (0.82, 1.39) 
* Unadjusted models only; no potential confounders were included in these models. 
1State model adjusted for age category and education. 
2Race model adjusted for metro status. 
3Education model adjusted for age category, gender, state, race, and metro status. 
4LD vaccine safety concerns model adjusted for age category, gender, education, HCP recommendation, 
past LD diagnosis in household, concern about future LD diagnosis, time spent in tick habitat, current use 
of LD prevention measures, general confidence in vaccines. 
5HCP influence on LD vaccination model adjusted for age category, gender, education, past LD diagnosis 
in household, concern about future LD diagnosis, time spent in tick habitat, general confidence in 
vaccines. 
6LD vaccine cost concerns model adjusted for age category, gender, state, education, HCP 
recommendation, concern about future LD diagnosis, time spent in tick habitat, current use of LD 
prevention measures, general confidence in vaccines. 
  
 In our sensitivity analysis using standard logistic regression to compare adjusted 
ORs and PRs, we found the two measures of association to be comparable (Appendix 
B, Table B.5). For the rarer “No” response to willingness to be vaccinated, the ORs and 
PRs were within a tenth of each other for all variables except education, LD vaccine 
safety concerns, and HCP influence on vaccination. For the less rare “Don’t know” 
responses, ORs and PRs were within 0.5 of each other. 
Discussion 
 We estimate that over 60% of residents living in areas with a high incidence of 
Lyme disease would be willing to receive a LD vaccine if one were available. 
Approximately 30% of residents were unsure about their willingness to be vaccinated, 
and they were more likely to be parents making decisions for their children, adults 45 – 
65 years of age, non-white, have less than a bachelor’s degree, or have concerns about 
the safety of a potential LD vaccine. Targeting vaccine communications to these groups, 
especially those in the age groups at highest risk for LD, may increase uptake of a LD 
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vaccine. Less than 10% of residents indicated that they were not willing to be 
vaccinated. They were also more likely to be non-white, have less than a bachelor’s 
degree, or have concerns about the safety of a potential LD vaccine, but they also 
would not be influenced by a positive recommendation from a HCP, have low 
confidence in vaccines in general, and have low perceived risk of contracting LD. 
Targeted outreach may be unlikely to change these groups’ willingness to receive a LD 
vaccine. Alternatively, these groups may have low perceived risk of LD because of truly 
being at low risk of LD (e.g., those living in more urban areas who do not spend time 
outdoors in tick habitat), and they may not benefit from LD vaccination. 
 A 2002 study among parents in Nassau County, New York evaluated whether 
parents would request the LYMErix vaccine for their children, if and when it became 
available. The vast majority said they would “definitely” (23%) or “likely” (65%) request 
it, followed by those “unlikely” (9%) to request it and those who would not (3%)[93]. 
While this response scale differs from that in our study, these results are similar to ours, 
with the majority willing to be vaccinated and few declining. Another study evaluated a 
LYMErix vaccination program among New York State Department of Health employees 
at risk for occupational tick exposure. While only 16% of employees chose to be 
vaccinated, the majority of non-recipients reported safety as a major concern, as seen 
in our results [94]. 
 Prior to the present study there has been little research on acceptability of a 
potential new LD vaccine, though a 2016 convenience sample survey conducted in 
Connecticut and Maryland counties with a high incidence of LD found that the majority 
of respondents were likely to receive a potential LD vaccine, with 49% “very likely”, 35% 
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“somewhat likely”, 8% “somewhat unlikely”, and 7% “very unlikely” [100]. Similarly, a 
nationwide population-based survey conducted in 2014 and 2015 found that 65% of 
respondents in high incidence states would be “likely” to receive a vaccine [101]. 
Additionally, a qualitative research study conducted in 2018 using focus groups of those 
at high risk for LD showed that 57% would be “very likely” to receive a LD vaccine 
(Devchand et al, submitted). Again, while the response scales of these studies differ 
from the present study, our estimates of potential vaccine uptake are concordant.  
 Demographic disparities in vaccination coverage are common and complex for 
both compulsory childhood vaccines and for recommended, non-compulsory vaccines 
for adults and children [70, 71, 90] [97-99]. Our finding that those who are non-white or 
those with lower education are more likely to respond “No” and “Don’t know” to LD 
vaccination contrasts somewhat with studies on childhood vaccines. In Arizona, non-
medical exemption rates (i.e., vaccine refusals) among kindergarteners were higher in 
schools with a higher proportion of white children and a lower proportion of free lunches 
(as  a proxy for income) [70]. In a nationwide survey, more white parents reported being 
unsure about or refusing childhood vaccinations versus other racial groups [71]. 
However, another nationwide survey found demographic differences when comparing 
under-vaccinated children with unvaccinated children; under-vaccinated children tended 
to be black, have a mother without a college degree, and have lower household income 
while unvaccinated children tended to be white, have a mother with a college degree, 
and have higher household income [90]. However, our survey was not parent-specific, 
and our sample includes only a small proportion of parent respondents. Our results for a 
voluntary LD vaccine are likely more comparable to annual reports of coverage for 
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recommended, non-compulsory vaccines for adults. Annually, these reports show 
higher coverage generally for whites compared with most other racial groups [97, 98]. 
Racial minorities are at risk for LD [140], and vaccine communications should focus on 
these groups in endemic areas.  
 Vaccine safety concerns are often cited as reasons for delaying or refusing 
vaccinations generally among both parents and adults, and these concerns were also 
an important factor in LYMErix vaccination decisions, despite it being proven to be safe  
[71-73, 90-94]. Our results show that safety will also be an important consideration in 
future LD vaccination decisions. A new LD vaccine may spawn additional safety 
concerns given that the waning demand for LYMErix was due, in part, to safety 
concerns, albeit unfounded. However, current vaccine candidates do not include the 
alleged, arthritis-causing epitope present in the LYMErix vaccine, which may assuage 
concerns for some [141]. Further, many studies, including this one, have shown that a 
positive recommendation for vaccination from a HCP has a significant influence on the 
vaccination decision and may increase uptake [92, 142, 143]. While other factors such 
as efficacy, convenience, and LD risk, among others, will undoubtedly play a role in 
uptake of a potential LD vaccine, effectively communicating its safety profile will be 
critical, and HCPs may be the best communicators of this information to the public 
[144]. As such, it will be important for public health practitioners to work with HCPs to 
develop messaging and other tools for communicating about a LD vaccine with patients. 
These results must be interpreted in the context of several potential limitations. 
While we anticipated and accounted for a low response rate in our sample size 
calculations, such large non-response may affect the validity of our estimate of vaccine 
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uptake due to non-response error. For example, it is possible that those who do not 
perceive themselves to be at risk for LD had low interest in the survey and chose not to 
respond. These non-respondents may be likely to decline LD vaccination due to their 
perceived low risk, thereby causing an overestimate of the proportion who would 
receive a LD vaccine in our sample, compared to the target population.  However, post-
stratification was intended to mitigate this non-response error. Further, Heckman 
selection model results did not reveal significant selection bias. In terms of information 
bias, most survey questions, including the willingness to be vaccinated outcome and 
independent variables of interest, concerned respondents’ opinions, making recall or 
misclassification error unlikely. However, given the hypothetical nature of the survey 
questions, the estimate of intention to receive a LD vaccine may change as more 
information on vaccine parameters becomes available or may differ from actual vaccine 
uptake. For example, results were mixed for studies evaluating the correlation between 
intention to receive a vaccine and actual uptake during the 2009-2010 influenza A/H1N1 
pandemic in the United States [145-147]. Lastly, while these results are generalizable to 
the populations of participating states, excluding residents of New York City, these 
results may or may not be generalizable to other states with a high incidence of LD. 
However, the states in this study represent a range of endemicity, from fully endemic in 
Connecticut to focally endemic in parts of Minnesota and New York; therefore, results 
are likely applicable to other endemic states, such as Massachusetts and Wisconsin, 
but may not apply to states where LD is emerging, such as Michigan and West Virginia. 
 In anticipation of a new LD vaccine coming to market, future studies should 
further evaluate parent-specific vaccine concerns, given that children are at high risk for 
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LD and may benefit most from the vaccine. Additional evaluations of vaccine 
acceptability will also be needed once safety, efficacy, dosing, and immunogenicity data 
is available for a new vaccine. Our estimate of potential vaccine uptake provides 
important information for ACIP recommendations and may be used in economic 
evaluations of a potential vaccine. Lastly, our characterization of the factors affecting 
willingness to receive a potential LD vaccine can inform future communication and 
education efforts with clinicians and the public to increase awareness and uptake of a 
vaccine. 
Conclusions 
LD incidence is increasing, despite current prevention options. A new LD vaccine 
could substantially reduce disease incidence if vaccine uptake is high. The majority of 
residents in four high incidence states would be willing to receive a LD vaccine if one 
were available. Effective communication by clinicians regarding safety, efficacy, and 
other vaccine parameters to those demographic groups who are uncertain about LD 
vaccination will be critical for increasing vaccine uptake and reducing LD incidence.  
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CHAPTER 5: COST-BENEFIT ANALYSIS OF VACCINATING A POPULATION 






An estimated 300,000 cases of Lyme disease occur in the United States annually, 
resulting in significant disease and cost burdens. New Lyme disease vaccines are 
currently in development, which have the potential to substantially reduce disease 
incidence, but the economic benefit of these vaccine candidates is unknown.  
Methods 
We conducted a cost-benefit analysis to estimate the net cost of vaccination against 
Lyme disease. We used a decision-analytic model to compare a vaccination strategy to 
no vaccination among 100,000 individuals living in high incidence areas over a three-
year time horizon. Vaccine and disease probabilities and costs were estimated from the 
literature as well as from primary research. Deterministic sensitivity analyses were 
conducted. Model outputs included cases averted, the net cost of the vaccination 
strategy, cost per case averted, and net cost per vaccinee. 
Results 
In the base-case analysis, we estimated that 2,160 cases would be averted during a 
three-year period for a 100,000-person cohort residing in an area with an incidence of 
0.01. The net cost of the vaccination strategy was $12,510,475, which translates to a 
cost per case averted of $9,301 and a net cost per vaccinee of $156 over a three-year 
period. The net cost per vaccinee was most sensitive to changes in disease incidence 
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and vaccine price, with a $0 net cost resulting from a vaccine price of $45 at an 
incidence of 0.01 or a vaccine price of $476 at an incidence of 0.08. 
Conclusions 
Many counties in endemic states have annual incidence greater than 0.01, and while 
the price of a potential vaccine is currently unknown, it is possible that an eventual 
vaccine could be cost saving. This analysis should be repeated when price and 
performance parameters for a Lyme disease vaccine are available. Results can inform 
recommendations for the use of a vaccine in the United States, when available. 
  




Lyme disease (LD) is a bacterial illness caused by infection with Borrelia 
burgdorferi, and more rarely, B. mayonii, in the United States (U.S.). It is primarily 
transmitted by the bite of infected Ixodes scapularis ticks in the northeastern, mid-
Atlantic, and upper-midwestern states [3, 4]. Cases of LD are increasing as the range of 
I. scapularis expands from historical foci and as human development intensifies in tick 
habitat [1, 5]. This multi-system disease is the most commonly reported vector-borne 
disease in the U.S. [1, 2], with bimodal incidence highest among children aged 5-10 
years and adults aged 45-55 years [1]. Annually, over 30,000 cases are reported to the 
Centers for Disease Control and Prevention (CDC), but recent studies have provided 
evidence that the true number of cases is estimated to be over 300,000 each year in the 
U.S. [6, 7]. In recent years, 95% of cases were reported from 14 states: Connecticut, 
Delaware, Maine, Maryland, Massachusetts, Minnesota, New Hampshire, New Jersey, 
New York, Pennsylvania, Rhode Island, Vermont, Virginia, and Wisconsin [1]. Though 
cases are concentrated geographically, this disease burden represents considerable 
direct and indirect costs to U.S. society [8](Aim 1, Chapter 3). The inability of currently 
available prevention measures to stem rising LD incidence highlights the need for a 
prevention modality suitable for use at the population level, such as a vaccine [17].  
An LD vaccine called LYMErix was available 1998 – 2002 in the U.S. until it was 
voluntarily discontinued by the manufacturer due to low demand caused by a number of 
factors unrelated to its positive safety and efficacy profiles [18-20]. Since then, the 
number of LD cases reported annually has nearly doubled [21]. After almost two 
decades without an effective prevention method, a new vaccine candidate called VLA15 
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[22-25] is being developed by the French biotech company, Valneva, in partnership with 
Pfizer [63-65]. This recombinant OspA-based vaccine candidate is being evaluated as a 
three-dose series for use in the general population, including children aged two years 
and older. It is designed to protect against the primary LD-causing strains found in both 
the U.S. and Europe. Randomized, observer-blind, placebo-controlled Phase II trials 
were completed in 2020 in LD endemic areas of the U.S. and Europe, with results 
showing both a favorable safety profile and high immunogenicity across all tested age 
groups. If successful, VLA15 may be licensed for use as early as 2024. In addition, a 
passive vaccination approach using a single monoclonal antibody administered annually 
is also in development [66-68]. This product, called Lyme pre-exposure prophylaxis 
(Lyme PrEP), is being developed by MassBiologics, a non-profit vaccine manufacturer 
overseen by the University of Massachusetts Medical School. MassBiologics plans to 
initiate Phase 1 trials in 2020 with potential availability in 2022 [66]. 
Three cost-effectiveness analyses were conducted for the LYMErix vaccine from 
1999 – 2002 [60-62], comparing a vaccination strategy with a no vaccination strategy. 
Results included incremental cost-effectiveness ratios ranging from $9,309 to $11,346 
(2020 USD) per LD case averted at an incidence rate of 0.01 [69]. When these cost-
effectiveness analyses were conducted, incidence rates close to 0.01 occurred only in a 
few counties in the northeastern U.S., which limited the overall economic benefit of the 
vaccine. With the number of reported cases currently growing and recent studies 
estimating true cases at approximately 10 – 12 fold higher [6, 7], there are now many 
more areas of the U.S. where incidence meets or exceeds 0.01, warranting an updated 
economic evaluation for a potential, new LD vaccine.  
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With recently available data on the direct and indirect costs per case of LD (Aim 
1, Chapter 3), we conducted a cost-benefit analysis comparing the costs and monetary 
benefits of a vaccination strategy with those of the current status quo (i.e., no vaccine 
strategy) using the societal perspective. Specifically, the primary objective of this project 
was to estimate the net cost of vaccination per vaccinee. The secondary objective was 
to identify variables that have the greatest impact on the net costs of vaccination. These 
estimates can be used to inform national recommendations by the Advisory Committee 
on Immunization Practices (ACIP) for the use of a LD vaccine, when available. 
Methods 
The Model 
We developed a decision-analytic model to assess the net costs or savings 
associated with a vaccination strategy compared to no vaccination. This approach is 
particularly appropriate for acute, non-communicable diseases occurring over a short, 
fixed time horizon, such as LD [107]. The decision tree used for the model is composed 
of branches and nodes, which are classified as either decision, chance, or terminal 
nodes. The structure of the decision-analytic model for this analysis included two main 
branches for the vaccination strategy; within the vaccination strategy, an individual 
chooses at the decision node whether to receive vaccination (Figure 5.1; see “Data” 
section below for associated probabilities for each node). The no vaccination strategy is 
not shown but is identical to the lower branch (“Vaccine not effective”) of the vaccination 
strategy wherein an individual chooses not to receive vaccination. 
 





Figure 5.1 Decision analysis tree used to model the costs and benefits of a Lyme 
disease vaccination strategy 
 
The vaccination strategy assumed use of a hypothetical Osp-A based, multi-
valent, sub-unit Lyme disease vaccine requiring three doses (i.e., VLA15), using 
available data on VLA15’s performance parameters when possible [65]. The decision-
analytic model was used to simulate a static cohort of 100,000 individuals living in LD 
endemic areas with an incidence of approximately 0.01 prior to vaccine introduction. We 
assumed that an individual’s vaccination decision in year one would be the same for 
subsequent years (i.e., those who were not vaccinated in year 1 remained 
unvaccinated). Therefore, for the vaccination strategy, the costs for the vaccine and its 
administration were included only in year 1. For the no vaccination strategy, all 
parameters were repeated annually. 
Reinfection with LD has been well documented [148]. Further, incidence in 
endemic areas is generally stable from year to year [1]. For these reasons, the model 
utilized a one-year cycle length wherein an individual’s risk for reinfection if not 
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vaccinated or if the vaccine was not effective is assumed to be the same annually. 
Duration of immunity after two years post-vaccination was not evaluated for LYMErix 
before its withdrawal [51, 52], and data on duration of immunity is not yet available for 
VLA15. For our model, we assumed that duration of immunity following vaccination 
would last at least three years based on the most optimistic duration of immunity from 
the LYMErix vaccine and assuming that the higher dose of vaccine used with VLA15 
compared to LYMErix would result in immunity at least as long [50, 61, 65]. Therefore, 
we chose a 3-year analytic time horizon for our model. Because it is currently unknown 
whether booster vaccinations will be needed for an eventual vaccine, booster dosing 
was not included in the model. 
Model Outputs 
The model outputs included the number of overall LD cases averted by the 
vaccination strategy compared to the no vaccination strategy; total cost of the 
vaccination strategy; the cost per case of LD averted; the net cost (or savings) of the 
vaccination strategy; and the net cost (or savings) per person vaccinated. The formulas 
for these outputs are listed in Table 5.1. All cost outputs were discounted at a 3.4% 
annual discount rate and given as their net present value [149]. 
Table 5.1 Lyme disease vaccine decision-analytic model outputs and formulas 
Output Formula 
Lyme disease cases 
averted with vaccination 
strategy 
Cases in no vaccination strategy – cases in vaccination strategy 
 
Cost of vaccination 
strategy 
Sum of costs of vaccination and illness in vaccination strategy 
 
Cost per case averted 
with vaccination 
strategy 
(Cost of vaccination strategy – Cost of no vaccination strategy*) /  
(Cases in vaccination strategy – Cases in no vaccination strategy) 
Net cost (or savings) of 
vaccination strategy 
(Cost of vaccination strategy – Cost of no vaccination strategy*) – (Benefit of 
vaccination strategy – Benefit of no vaccination strategy*) 
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Net cost (or savings) 
per vaccinee  
(Cost of vaccination strategy – Cost of no vaccination strategy*) – (Benefit of 
vaccination strategy – Benefit of no vaccination strategy*) / number 
vaccinated in vaccination strategy 
*The no vaccination strategy represents the status quo. As such, the cost of the no vaccination strategy 
as well as the benefit of the no vaccination strategy equals $0. 
 
Data 
The probability and cost variables used in the model are shown in Tables 5.2 and 
5.3, respectively, and were estimated from the literature (see references in Table 5.2), 
Aim 1 (Chapter 3), and Aim 2 (Chapter 4). For each variable, we assigned a best 
estimate for use in the base-case analysis, as well as a clinically plausible range to use 
in deterministic sensitivity analyses. 
Table 5.2 Base-case probability estimates and plausible ranges 
Variable Estimate Range Reference 
Vaccination    
 Efficacy 0.9 0.7 – 0.99 [51, 52, 64, 65] 
 Uptake 0.8 0.64 – 0.94 Aim 2 (Ch. 4) 
Lyme disease    
Incidence, endemic states 0.01 0.001 – 0.08 [1, 6, 7, 150] 
Confirmed, localized Lyme disease 0.55 0.50 – 0.9 [1, 21] 
Confirmed, disseminated Lyme disease 0.21 0.1 – 0.3 [1, 21] 
Probable Lyme disease 0.24 0.1 – 0.5 [1, 21] 
Sequelae     
Confirmed, localized Lyme disease 0.03 0.00 – 0.07 [37, 60, 62, 123] 
Confirmed, disseminated Lyme disease 0.26 0.18 – 0.28 [60, 62, 123] 
Probable Lyme disease 0.14 0.10 – 0.18 [60, 62, 123] 
Suspected Lyme disease (i.e., tested, non-Lyme 
disease) 
   
Incidence, suspected Lyme disease 0.061 0.057 – 0.063 [7] 
Incidence, suspected Lyme disease if vaccinated 0.012 0.011 – 0.013 [7] 
 
Vaccine parameters 
 Instead of assuming that 100% of our hypothetical cohort would receive 
vaccination in the vaccination strategy, we used an estimate of uptake derived from Aim 
2 to reflect a more realistic scenario. In Aim 2, we estimated that, of those living in 
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endemic areas, 63.6% would be willing to receive vaccination against LD, 29.6% were 
uncertain, and 6.7% were not willing. For the present model, we assumed that a portion 
of those who were uncertain would ultimately choose vaccination; therefore, our base-
case estimate of the probability of vaccine uptake was 0.80, with a lower bound of 0.64 
and an upper bound of 0.94. 
 In our model, we estimated that the base-case probability for vaccine efficacy 
was 0.9 based on the most recent data released from VLA15’s second Phase II trial 
[65]. This trial found that seroconversion rates among those vaccinated exceeded 90% 
across all six B. burgdorferi serotypes for all ages tested (18 – 65 years). Generally 
speaking, seroconversion signifies protection against infection in most scenarios [151]. 
Phase III clinical trials for LYMErix and ImmuLyme, a similar OspA vaccine candidate 
that was never licensed, demonstrated vaccine efficacy ranging from 49 – 68% for two 
doses and 76 – 77% for three doses [51, 52]. However, the dose for the previous 
vaccines was much lower than the current candidate (30 µg of OspA for LYMErix vs. 
135 µg or 180 µg for VLA15) and different dosing schedules were used. Therefore, we 
chose a lower bound of 0.7 to approximate efficacy with reduced compliance of only 2/3 
doses of VLA15, or in the event that vaccine efficacy for VLA15 is eventually shown to 
be similar to that of LYMErix. We assumed an upper bound of 0.99 under a scenario of 
an optimal dosing and administration schedule. We did not account for adverse events 
related to vaccination in our model because no significant adverse events were reported 
in either Phase II trial for VLA15. 




The annual risk for infection with LD is derived from incidence rates based on 
reported cases in highly endemic states; these numbers are then multiplied by 10 to 
account for the rate of underreporting for LD and approximate true incidence [6, 7]. For 
clinical outcomes, we used surveillance data to estimate probabilities associated with 
confirmed localized disease (i.e., presence of erythema migrans or early disease), 
confirmed disseminated disease (i.e., cardiac, neurologic, and/or rheumatologic 
symptoms resulting from disseminated infection), and probable disease. The probable 
disease category includes those with a physician diagnosis of LD and laboratory 
evidence of infection but no accompanying clinical information. This category may 
include some individuals without true LD (e.g., those with past infection) whose 
symptoms and associated costs are nevertheless attributed to LD. Probabilities for 
these three categories are derived from the average proportion of confirmed cases 
reported 2008 – 2017, multiplied by the proportion of reported erythema migrans (for 
confirmed localized disease) or the proportion of reported non-erythema migrans 
symptoms (for confirmed disseminated disease), respectively, for the same time period 
[1, 21]. The probability associated with a probable disease outcome was derived from 
the average proportion of probable cases reported 2008 – 2017 [1, 21].  
Estimates of the probabilities of sequelae, defined as persistent symptoms for six 
months or more after confirmed LD [29], were derived from the literature. We assumed 
the base-case probability of sequelae resulting from localized disease to be 0.05 (range 
0 – 0.07) [37] and sequelae resulting from disseminated disease to be 0.26 (range 0.18 
– 0.28); the latter was derived by averaging probabilities for specific manifestations 
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(e.g., cardiac, neurologic, or arthritic) [60-62]. Sequelae resulting from probable disease 
was estimated to be an average of localized and disseminated disease parameters 
(0.14, range 0.09 – 0.18). 
We defined suspected LD cases as those who were tested for LD, and as such, 
incurred testing costs but did not have evidence of current B. burgdorferi infection. 
Probabilities for suspected LD were derived from Hinckley et al. 2014 [7]. This study 
estimated that 88% (range 81.5 – 90%) of diagnostic tests conducted for LD by four 
large commercial laboratories were for non-infected individuals. We multiplied the total 
number of specimens (2,432,396, used as proxies for individuals) tested by these 
laboratories by the proportion non-infected (0.88) and the proportion of specimens from 
four endemic states (0.31), resulting in an estimate of 663,558 (range 614,570 – 
678,666) suspected LD cases in these states (Connecticut, Maryland, Minnesota, and 
New York). These four states represent 36% of all reported LD cases; applied to an 
annual, nationwide total of 300,000 cases, these four states, therefore, account for 
108,000 cases. We then calculated the ratio of suspected LD cases (663,558) to true 
LD cases (108,000) to get a multiplier of 6.14. This multiplier was applied to the 
incidence rate in endemic areas (0.01) for a resulting base-case suspected LD 
incidence rate of 0.0614 (range 0.0569 – 0.0628), which was used in the no vaccine 
strategy. For the vaccine strategy, we assumed that this rate would decrease by 80% 
among those vaccinated, resulting in a base-case estimate of 0.0123 (range 0.0114 – 
0.0126). 




The cost-benefit analysis was conducted from a societal perspective, including all 
direct and indirect costs of vaccine administration and illness, regardless of who is 
responsible for these costs. The costs of the vaccination strategy represented the sum 
of the costs of vaccination (vaccine and its administration) and the costs associated with 
LD cases that occurred in the vaccination strategy. The benefits of the vaccination 
strategy are equivalent to the cost of LD cases averted due to vaccination. All costs 
included in the model were adjusted for inflation to 2020 U.S. dollars using the medical 
care component of the consumer price index [113]. The base-case estimates, plausible 
ranges, and references for the cost variables are given in Table 5.3. 
Table 5.3 Base-case cost estimates and plausible ranges 
Variable Estimate Range Reference 
Costs (USD 2020)    
Vaccination series and administration 213 28 – 684   [59] 
Confirmed, localized Lyme disease 1,461 173 – 2,994  Aim 1 (Ch. 2) 
Confirmed, disseminated Lyme disease 3,634 332 – 6,973 Aim 1 (Ch. 2) 
Probable Lyme disease 2,929 353 – 5,613 Aim 1 (Ch. 2) 
Sequelae 17,295 7,728 – 23,322 [62, 123, 124] 
Diagnostic testing for suspected Lyme disease 322 237 – 400  [7] 
 
The base-case estimate of the cost of the three-dose vaccination series was 
derived from the Centers for Disease Control and Prevention’s (CDC) Vaccine Price 
List, updated September 2020 [59]. Vaccines for adults and children were selected for 
which three doses are required. The CDC cost per dose and private sector cost per 
dose were averaged per vaccine, then multiplied by three to get an average series cost 
per vaccine. Our base-case vaccine series cost was estimated as the average series 
cost from all vaccines selected from the Vaccine Price List. Our series cost range was 
based on the minimum and maximum series costs derived from the Vaccine Price List. 
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We did not include costs associated with vaccine side effects as no serious adverse 
events have been reported for VLA15, as described above. 
The cost estimates for LD cases by confirmed localized, confirmed disseminated, 
and probable disease were derived from Aim 1 (See Chapter 3 for details on 
methodology. See Appendix C, Table C.1 for summary statistics of costs by disease 
category.). The costs by disease category include direct costs for medical care for LD 
as well as indirect costs for LD, including productivity losses and non-medical costs 
incurred by the patient (e.g., transportation costs to receive medical care for LD). For 
this analysis, the mean cost per person by disease category was used in the base-case 
analysis, with the 10th and 90th percentiles used for the plausible range (Table 5.3; 
Appendix C, Table C.1). The cost of disease sequelae was derived from the literature 
[62, 123, 124]; we averaged the estimates for arthritic, cardiac, and neurologic sequelae 
for a single base-case cost estimate and plausible range. 
The cost of suspected LD was derived from Hinckley et al. 2014, similar to the 
derivations for the probability of suspected LD [7]. Hinckley et al. (2014) estimated the 
total cost of testing ($492M in 2008 USD); we multiplied this by the proportion of all 
negative tests (0.88) and the proportion in four endemic states (0.31). We then divided 
this cost by the number of individuals with suspected LD (663,558) for an average per-
person cost of testing. This cost was added to an average office consultation cost and 
routine venipuncture cost for a base-case estimate of $322 per person (range $237 – 
400; 2020 USD). 




Deterministic sensitivity analyses were conducted to evaluate uncertainty in 
results and determine which variables have the greatest impact on the net cost per 
vaccinee, defined as the variables resulting in the greatest range between the minimum 
and maximum change in the net result [106]. In one-way sensitivity analyses, LD 
incidence, vaccine efficacy, clinical probabilities, and cost estimates were each varied 
over their plausible ranges to estimate changes in model outputs. The two most 
influential variables were evaluated in a two-way sensitivity analysis, and threshold 
analysis was conducted to determine the values at which these two variables resulted in 
a $0 net cost (i.e., the point at which the result changes from net cost to net savings) 
[106]. Lastly, we conducted an analysis of extremes, sometimes referred to as 
“worst/best case analysis” [106]. With this method, the extreme estimates from the 
plausible ranges of all model parameters are fixed under two scenarios, one that favors 
and one that does not favor vaccination (e.g., a low cost, high effectiveness scenario or 
a high cost, low effectiveness scenario, respectively). Herein, we have termed these 
“optimistic scenario” and “pessimistic scenario,” respectively (Appendix C, Table C.2). 
Results 
 In the base-case analysis, we estimated that 2,160 cases of LD would be averted 
during a three-year period for every 100,000 persons (i.e., 80,000 persons vaccinated 
per the vaccine uptake parameter) living in an endemic area with an incidence of 0.01 
(Table 5.4). The net cost of the vaccination strategy in the base-case analysis was 
$12,510,475, which translates to a cost per case averted of $9,301 and a net cost per 
vaccinee of $156 over a three-year period. 
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 In the optimistic scenario, when all vaccine parameters were set to their 
extremes favoring vaccination (Appendix C, Table C.2), we estimated that 22,334 cases 
of LD would be averted during a three-year period (Table 5.4). In this scenario, the net 
savings of the vaccination strategy was $131,788,122, which results in a cost per case 
averted of $616 and net savings per vaccinee of $1,402. In the pessimistic scenario, 
when all vaccine parameters were set to their extremes that do not favor vaccination 
(Appendix C, Table C.2), we estimated that 134 cases of LD would be averted during a 
three-year period. In this scenario, the net cost of the vaccination strategy was 
$42,507,925, which results in a cost per case averted of $316,848 and a net cost per 
vaccinee of $664. 
Table 5.4 Base-case, optimistic, and pessimistic scenarios for a Lyme disease vaccination 
strategy compared to a no vaccination strategy among a 100,000-person cohort 




Cost per case 
averted (USD 
2020) 
Net cost of 
strategy (USD 
2020) 





      
 No vaccine 16,096,564 3,000 NA NA NA NA 
 Vaccine 20,089,797 840 2,160 9,301 12,510,475 156 
Optimistic 
scenario 
      
 No vaccine 163,466,390 24,000 NA NA NA NA 
 Vaccine 13,751,460 1,666 22,334 616 -131,788,122 -1,402 
Pessimistic 
scenario 
      
 No vaccine 3,988,705 300 NA NA NA NA 
 Vaccine 42,584,410 166 134 316,848 42,507,925 664 
 
 In one-way sensitivity analyses, the cost of the vaccine (plausible range $28 – 
684) had the greatest effect on the main outcome, ranging from a net savings of $17 to 
a net cost of $597 per vaccinee (Figure 5.2). Increasing vaccine cost had the greatest 
potential to increase the net cost per vaccinee of all parameters. Endemic incidence 
(plausible range 0.001 – 0.08) had the second greatest effect on the net cost per 
vaccinee, ranging from a net savings of $248 to a net cost of $208. Increasing incidence 
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had the greatest potential for net savings per vaccinee of all parameters. In an 
additional sensitivity analysis using the minimum and maximum costs per disease 
category found in Aim 1 (Chapter 3), vaccine price and disease incidence still had the 
greatest impact on net cost per vaccinee, but the cost of disease also had a large effect 
on results, with increasing probable disease and confirmed disseminated disease cost 




Figure 5.2 Impact of select model parameters on the net cost per Lyme disease 
vaccinee resulting from one-way sensitivity analyses* 
 
*Probabilities for suspect Lyme disease (LD), cost of suspect LD, and probabilities for sequelae had a 
negligible impact on the net cost per vaccinee and were not included in the plot.  
**Vaccine cost and confirmed localized disease probability have a positive relationship with net cost per 
vaccinee. All other parameters have a negative relationship with net cost per vaccinee. 
 
 In a two-way sensitivity analysis varying the parameters with the greatest impact 
in one-way sensitivity analyses, vaccine price and LD incidence, we found that at the 
lower bound incidence of 0.001, there were no net savings per vaccinee at any vaccine 
price (Figure 5.3; Appendix C, Figure C.2). At the base-case incidence of 0.01, there is 
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a potential for net savings per vaccinee at lower vaccine costs, and the breakeven 
vaccine price was $45 for a $0 net cost per vaccinee. At the upper bound incidence of 
0.08, there is a potential for net savings per vaccinee up to a vaccine price of $476, 
which is the breakeven price for a $0 net cost per vaccinee. 
 
Figure 5.3. Net cost per vaccinee in two-way sensitivity analysis of Lyme disease 
vaccine price and Lyme disease incidence 
 
Discussion 
In this cost-benefit analysis, a LD vaccination strategy among a hypothetical 
cohort of 100,000 individuals living in endemic areas resulted in over 2100 cases 
averted during a three-year time period in our base-case scenario. The net cost of the 
vaccination strategy was $12.5M and the net cost per vaccinee was approximately 
$150, corresponding to a net cost per vaccinee per year of approximately $50. Vaccine 
price and LD incidence had the greatest influence on model results. At an incidence of 
0.01, the vaccination strategy became cost-saving at a vaccine price of $45 per person. 
When a rate of 10 – 12 fold underreporting of LD cases is taken into account [6, 7], 
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many counties have annual incidence greater than 0.01, increasing the likelihood that a 
LD vaccine could be cost saving, particularly if the eventual vaccine price is < $200 
(Appendix C, Figure C.1). 
 Several cost-effectiveness analyses were conducted for the previously available 
LYMErix vaccine, and these findings may be compared to our results for cost per case 
averted of $9,301 at an incidence of 0.01, vaccine price of $213, and other base-case 
estimates of parameters (Table 5.2). Meltzer et al. estimated a cost per case averted of 
$10,143 (USD 2020) annually with a vaccination cost of $100 per year at an incidence 
of 0.01 [60]. Shadick et al. estimated a cost per case averted of $11,346 (USD 2020) 
with a vaccination cost of $150 at an incidence of 0.01 [62]. Hsia et al. estimated a cost 
per case averted of $9,309 (USD 2020) with a vaccination cost of $621, which included 
the cost of a booster vaccination at 3 years [61]. All three studies concluded that LD 
incidence was the most important factor in determining cost-effectiveness for a LD 
vaccine and that at > 0.01 incidence, a LD vaccine was potentially cost-effective, but 
that individual risk should be taken into account when recommending the LYMErix 
vaccine.  These findings are comparable to our cost-effectiveness results, though 
important differences in probability and cost estimates for model parameters should be 
noted. These cost-effectiveness analyses assumed universal vaccination of the cohorts 
used in their models, while we included an estimate of vaccine uptake (0.8) derived 
from Aim 2 (Chapter 4). Further, these studies estimated vaccine efficacy at 0.76 – 0.85 
based on the data available for LYMErix at the time. Our higher base-case estimate of 
0.9 vaccine efficacy is derived from interim clinical trial data for VLA15 and assumes full 
compliance for the three-shot series [65, 152]. These studies used probabilities and cost 
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for disease and sequelae based on clinical outcomes by symptom category (neurologic, 
cardiac, and arthritis), while our study categorized disease based on surveillance data 
for confirmed localized disease, confirmed disseminated disease, and probable disease. 
Finally, these studies did not have data available on the total cost of LD per person, and 
all but Meltzer et al. used direct costs only for the treatment of LD. Our use of the total 
cost of LD per person from the societal perspective from Aim 1 included all direct and 
indirect costs associated with LD. This difference allowed us to monetize the benefit of a 
case averted and go beyond estimating cost-effectiveness to estimating the net cost or 
savings of a LD vaccine. 
Currently, cost-benefit analyses for other LD prevention methods do not exist, 
such as for residential acaricide treatments, residential rodent-targeted bait boxes, or 
permethrin treated clothing. While the annual cost per person for these interventions 
may be comparable to the cost of a LD vaccine [Niesobecki et al, in press], the 
effectiveness of these interventions in terms of cases averted remains unknown. Recent 
studies have evaluated residents’ willingness to pay to avoid risk of contracting LD (i.e., 
avoidance of habitat with ticks infected with B. burgdorferi) as evidenced by substituting 
away from outdoor recreation in areas with LD risk or by their willingness to travel 
further to lower-risk recreational areas [153, 154]. Berry et al. estimated an average of 
9.41 hours annually are substituted away from outdoor activity due to LD risk at an 
estimated cost of $210 per person (USD 2020) annually, significantly higher than the 
estimated $50 net cost of LD vaccination per person annually found in the present 
study. Slunge estimated that residents in Sweden were willing to pay $30 (USD 2020) 
more per recreational trip in the form of traveling further to avoid areas with many ticks 
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and risk for Lyme borreliosis. Assuming a similar willingness to pay in the U.S. and that 
people take at least two outdoor recreation trips per year, willingness to pay to travel 
further to reduce risk of LD is greater than the $50 net cost of vaccination per person 
annually. However, Slunge also found that the willingness to pay to avoid ticks was 
lower among persons vaccinated against tick-borne encephalitis, suggesting there may 
be an additional benefit of vaccination in the form of increased leisure time spent 
outdoors in endemic areas [153]. 
 While many vaccinations are consistently cost-saving, such as routine childhood 
vaccinations [155], there are recommended immunizations that generate a net cost 
depending on disease incidence, target population, vaccination strategy, and other 
factors. For example, influenza vaccinations may generate a net cost depending on the 
match between the circulating strain and available vaccine [156, 157]. Vaccination 
against tick-borne encephalitis among French troops in the Balkans resulted in a net 
cost, primarily due to low incidence of the disease, despite its associated high morbidity 
and mortality [158]. In addition, economic analyses of meningococcal vaccines have 
shown that costs usually outweigh the benefits, yet it remains recommended for those 
at risk due to associated high morbidity and mortality, even with adequate treatment 
[159, 160]. Similarly, setting priorities for vaccination against LD will likely not be based 
solely on economic considerations but on the relative risks of certain groups for serious 
complications, the overall burden of disease in the U.S., and the lack of effective 
prevention alternatives, among other factors.  
Every attempt was made to select representative estimates for the probabilities 
and costs used in our model, however these findings are valid only insofar as the 
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parameters and assumptions included in the model are valid. Because this project uses 
primary data from Aims 1 (disease cost) and 2 (vaccine uptake), it is subject to the 
limitations for these projects described in previous chapters (chapters 3 and 4). In 
addition, the vaccination costs used in the model are considered marginal costs and do 
not account for development of or upgrades to the basic infrastructure necessary for a 
vaccine program; thus, general administrative costs may be underestimated [161, 162]. 
While we did not include costs associated with vaccine side effects because no serious 
adverse events have been reported in the most recent Phase II trials for VLA15, 
subsequent, larger Phase III trials may reveal risk for serious adverse events which 
should be included in future cost-benefit analyses and would influence results away 
from cost savings. Further, we did not include the cost of productivity losses associated 
with death due to LD as this outcome is exceedingly rare; however, inclusion of this cost 
would influence results toward cost savings. Vaccination against LD will not prevent 
infections with other pathogens transmitted by I.scapularis ticks such as Anaplasma 
phagocytophilum, Babesia microti, Powassan virus, and B. miyamotoi. While these 
diseases are much less common than LD, vaccination may cause people to reduce their 
usual measures for preventing I. scapularis tick bites and increase risk for these other 
diseases, thereby creating an additional cost associated with LD vaccination. For the 
purposes of this analysis, we assumed current prevention behaviors would continue to 
be employed with the availability of a LD vaccine. Regarding probabilities used for 
disease categories, these were derived from surveillance data, with likely overreporting 
of rarer, disseminated disease and underreporting of more common, early localized 
disease occurring [122]. However, the plausible ranges for these probabilities account 
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for these potential inaccuracies, and disease probabilities did not have a large impact 
on the net cost per vaccinee in sensitivity analyses. Lastly, as a new LD vaccine is not 
currently licensed and available, there are uncertainties surrounding vaccine efficacy, 
vaccine effectiveness, duration of immunity, and dosing schedule. If boosters are 
required with VLA15, this will drive up the net cost per vaccinee and require future 
analysis over a longer time horizon. In addition, if vaccinees receive only one or two of 
the required doses, this will reduce vaccine efficacy and increase the net cost per 
vaccinee. As more definite data for these parameters become available, the model can 
be modified to incorporate these changes. The model may also be easily adjusted for 
economic evaluations of other future vaccines or vaccine-like candidates, such as Lyme 
PrEP. 
Conclusions 
 LD incidence is increasing, despite current prevention options, but a new LD 
vaccine could substantially reduce disease incidence. While our base-case analysis did 
not find a hypothetical LD vaccine to be cost-saving from a societal perspective, those 
living in endemic areas may be willing to pay out of pocket for the net cost of $150 per 
vaccinee estimated from our analysis for at least three years of protection. Our 
sensitivity analysis showed that the net cost (or savings) was very sensitive to vaccine 
price and LD incidence. Because many counties in LD endemic states have annual 
incidence greater than our base-case estimate of 0.01, and because the price of a 
potential vaccine is currently unknown, there is potential that an eventual vaccine could 
be cost-saving. This analysis should be conducted in the future when exact 
performance parameters for a vaccine or vaccine-like preventive is available. 
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The body of work described in this dissertation provides critical information for 
public health considerations for a potential Lyme disease (LD) vaccine in the United 
States (U.S.). Specifically, this research provides new information on the economic 
burden of LD, the acceptability of a potential LD vaccine by the public, and the net cost 
of a potential vaccination program. We found that most LD patients have low costs, but 
some experience very high costs related to LD; further, the total economic burden of 
diagnosed LD in the U.S. could be upwards of $800 million annually, a significant 
societal cost. We also found that acceptance of a LD vaccine among potential 
consumers was high, with over 60% willing to receive vaccination, approximately 30% 
uncertain, and less than 10% unwilling. Lastly, using these cost and vaccine 
acceptability results, we estimated that a vaccination program in areas with a high 
incidence of LD could generate a net cost of approximately $150 per vaccinee over 
three years of vaccine effectiveness; however, a vaccination program could potentially 
be cost-saving depending on the eventual price of a LD vaccine and disease incidence. 
With currently available prevention measures failing to decrease LD incidence, new 
vaccine candidates have the potential to make a substantial impact on the morbidity and 
economic burden of LD in the U.S. 
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Individual project conclusions and next steps 
Aim 1: The Economic Burden of Reported Lyme Disease in High Incidence Areas of the 
United States 
In a prospective, cost of illness study conducted in Connecticut, Maryland, 
Minnesota, and New York, we found patients had an average out-of-pocket cost of 
approximately $1,340 (median cost ≈ $270) and an average total cost of approximately 
$2,270 (median cost ≈ $770) (2020 USD). In stratified analyses by disease category, 
those with confirmed disseminated and probable disease had approximately double or 
more the total cost per patient compared to those with confirmed localized disease, 
highlighting the importance of early and accurate diagnosis. Having disseminated or 
probable disease, being aged 18 – 65 years, and having residence in Minnesota had 
the greatest impact on the total cost of LD. While median total costs were typically 
$1,000 or less for all disease categories, average costs were substantially higher, 
indicating that most patients have low costs, but some experience very high costs 
related to LD. Similarly, the low median number of provider visits and hours of lost 
productivity suggest that illness with LD is manageable for most, but for a minority, it 
may be highly disruptive. With over 300,000 cases of LD diagnosed each year, the 
aggregate cost of diagnosed LD could be upwards of $800 million (2020 USD) annually, 
not including suspected, undiagnosed, or non-acute LD. These costs represent a 
significant economic burden to U.S. society and underscore the need for effective 
prevention methods. Future efforts should include use of these results in economic 
evaluations of current and future prevention methods, such as a vaccine. In addition, 
more research is needed to determine the cost of unreported, suspected, and non-acute 
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LD for an even more comprehensive estimate of the economic burden attributable to LD 
in the U.S. 
Aim 2: Evaluating public acceptability of a potential Lyme disease vaccine using a 
population-based, cross-sectional survey in high incidence areas in the U.S.  
From the results of a population-based, cross-sectional survey conducted in 
Connecticut, Maryland, Minnesota, and New York, we estimated that over 60% of 
residents in states with a high incidence of Lyme disease would be willing to receive 
vaccination if a LD vaccine were available. Approximately 30% of residents were unsure 
about their willingness to receive LD vaccination, and they were more likely to be 
parents making decisions for their children, adults 45 – 65 years of age, non-white, have 
less than a bachelor’s degree, or have concerns about the safety of a potential LD 
vaccine. Targeting vaccine communications to these groups, especially those in the age 
groups at highest risk for LD, may increase uptake of a LD vaccine. Less than 10% of 
residents indicated that they were not willing to receive LD vaccination. They were also 
more likely to be non-white, have less than a bachelor’s degree, or have concerns about 
the safety of a potential LD vaccine, but they also would not be influenced by a positive 
recommendation from a HCP, have low confidence in vaccines in general, and have low 
perceived risk of contracting LD. Targeted outreach may be unlikely to change these 
groups’ willingness to receive LD vaccination. Effective communication by clinicians 
regarding safety, efficacy, and other vaccine parameters to those demographic groups 
who are uncertain about LD vaccination will be critical for increasing vaccine uptake. 
Next steps should include conducting a larger study among parents of minors to further 
elucidate factors contributing to LD vaccine hesitancy, as children are one of the groups 
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at highest risk for LD. Further, vaccine acceptability studies should be conducted among 
clinicians providing primary care to patients living in endemic areas. These results will 
allow for targeted messaging among consumers and clinicians to increase vaccine 
awareness and acceptability, and will also aid in the development of communication 
tools to assist clinicians in discussing the LD vaccine with patients.  
Aim 3: Cost-benefit analysis of a strategy to vaccinate a population against Lyme 
disease in high incidence areas of the U.S.  
In this cost-benefit analysis, a LD vaccination strategy among a hypothetical 
cohort of 100,000 individuals living in endemic areas resulted in over 2,100 cases 
averted during a three-year time period in the base-case scenario, which included an 
LD incidence of 0.01 and a vaccine price of approximately $200. The net cost of the 
vaccination strategy was $12.5M and the net cost per vaccinee was approximately 
$150, corresponding to a net cost per vaccinee per year of approximately $50. 
Individuals living in endemic areas may be willing to pay $150 out of pocket for at least 
three years of protection. Vaccine price and LD incidence had the greatest influence on 
model results. At an incidence of 0.01, the vaccination strategy became cost-saving at a 
vaccine price of $45 per person. When a rate of 10 – 12-fold underreporting of LD cases 
is taken into account, many counties have annual incidence greater than 0.01, 
increasing the likelihood that a LD vaccine could be cost saving, particularly if the 
eventual vaccine price is < $200. This analysis should be conducted in the future when 
exact performance parameters of a vaccine are known, such as efficacy, duration of 
immunity, dosing schedule, price, and frequency of adverse effects. To aid in future 
resource allocation decisions, the decision-analytic model used for the present analysis 
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may be adjusted as needed for a new vaccine, such as VLA15; a vaccine-like 
preventive, such as Lyme PrEP; or even for a non-vaccine LD intervention. Additional 
economic studies should be conducted to determine how much potential consumers 
would be willing to pay for a LD vaccine to further enhance understanding of public 
acceptability of a vaccine and aid decision-makers in vaccine financing decisions. 
Overall contribution and impact 
The Advisory Committee on Immunization Practices (ACIP) is hosted by the 
Centers for Disease Control and Prevention (CDC) but is comprised of immunization 
experts from academia, professional organizations, clinical practice, industry, and public 
health. This committee meets several times a year to make national recommendations 
for the use of licensed vaccines based on factors such as disease burden, public 
acceptance, public health impact, cost, vaccine supply, and other considerations 
beyond the safety and efficacy data used for FDA approval [58]. These 
recommendations become CDC policy upon publication in the Morbidity and Mortality 
Weekly Report and are the principal guide for clinicians in vaccination decisions for 
individual patients. The primary results from all three Aims provide important, 
complementary information that may be considered by the ACIP in making 
recommendations for a new LD vaccine, when available. Specifically, these results 
show the need for, potential public demand for, and economic benefit of a new LD 
vaccine. Further, these results include much more information than was available to the 
ACIP in 1998 when the committee made what many regard as lukewarm 
recommendations for the formerly available LD vaccine, LYMErix [17, 50, 57]. It is 
possible that the current, robust collection of findings will result in stronger 
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recommendations for a new LD vaccine for those living in any state with a high 
incidence of LD (i.e., Connecticut, Delaware, Maine, Maryland, Massachusetts, 
Minnesota, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, 
Vermont, Virginia, and Wisconsin), for those living in counties in other states where LD 
is emerging, and potentially for those planning to travel to these areas [1]. 
The results from the cost of illness study described in Aim 1 (Chapter 3) add to 
the small but growing body of literature on the economic burden of LD in the U.S. A 
major strength of this study over previous ones is its prospective collection of patient 
out-of-pocket costs, including productivity losses, thereby providing a comprehensive 
estimate of the cost of LD, both to the patient and to society as a whole. These results 
illustrate the economic burden of LD in the U.S., but can also be used in economic 
evaluations of a vaccine and non-vaccine LD interventions. The LD vaccine 
acceptability study (Aim 2, Chapter 4) generated some of the first estimates of uptake 
for a past or future vaccine in the U.S. These results also provide a critical variable in 
the cost-benefit analysis, allowing for a more realistic estimate of the cost or benefit of a 
vaccination program. The cost-benefit analysis (Aim 3, Chapter 5) is the first of its kind 
for a LD vaccine, as previous economic evaluations of the formerly available LYMErix 
vaccine did not have comprehensive cost of illness data available and were thus limited 
to cost-effectiveness analyses. While cost-effectiveness results allow for a comparison 
of the cost of different interventions for the same health outcome, the results of a cost-
benefit analysis allow for a comparison of the net cost of the intervention of interest to 
any other intervention, whether for the same or a different health outcome, or 
alternatively, for a health outcome vs. a non-health outcome. For example, the federal 
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government may use the results from Aim 3 in resource allocation decisions regarding 
vaccination programs for LD vs. dengue; or, it may compare the net cost of a LD 
vaccination program to an environmental intervention.  
While the impacts of our primary results described above are directly relevant to 
ACIP considerations for a potential vaccine, the findings from the secondary objectives 
of this suite of research also have important public health implications for improving the 
prevention and control of LD. The cost of illness results in Aim 1 highlight patient 
characteristics associated with higher costs, which can be used to improve economic 
efficiency in the clinical management of LD. The characterization of factors associated 
with willingness to receive a LD vaccine in Aim 2 will allow for more targeted 
communications among the public and clinicians about a new vaccine to prevent some 
of the challenges that led to the demise of the LYMErix vaccine. Lastly, because we 
found that the results of the cost-benefit analysis were very sensitive to disease 
incidence, the model could be transformed into a decision tool for use by state and local 
public health practitioners to generate net cost results based on local incidence at 
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APPENDIX A: SUPPLEMENTAL MATERIALS FOR CHAPTER 3, THE ECONOMIC 
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Section A.1 Detailed description of cost calculations for out-of-pocket patient 
costs and direct medical costs 
To estimate the out-of-pocket costs per patient, we summed self-reported 
medical costs, non-medical costs, cost of productivity losses, and other related costs 
over all surveys. For non-medical costs related to travel for clinician, pharmacy, or lab 
visits, the self-reported roundtrip mileage per visit was multiplied by the standard 
mileage rate from the Internal Revenue Service for the respective year [163]. To 
calculate cost estimates for productivity losses, self-reported hours missed from work 
for adult patients or parents of pediatric patients were multiplied by the hourly earnings 
by age and sex derived from Grosse et al. 2019 [164], which uses the human capital 
approach to estimate annual market and non-market productivity from the U.S. Census 
Bureau’s American Community Survey and American Time Use Survey. 
We calculated the direct medical cost per patient by summing the mean cost per 
CPT code collected for each patient. Mean cost for each CPT code collected for 
participants with private insurance was extracted from IBM® MarketScan® Research 
Databases, which include national medical claims data for privately insured persons up 
to age 65 and their dependents. Costs for CPT codes collected for non-privately insured 
participants were extracted from the Physician Fee Schedule National Payment Amount 
File from the Centers for Medicare and Medicaid Services (CMS) [112]. We did not 
collect billing codes from pharmacies or laboratories. Therefore, we extracted the mean 
cost of the recommended antibiotics for LD by state and study year from MarketScan® 
drug cost data and added this cost to each participant’s total direct medical cost [165-
169]. Because laboratory evidence of infection is required to meet criteria for confirmed 
disseminated or probable disease [47], we added the cost of the recommended two-
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tiered LD diagnostic testing to the total direct medical cost for all participants in these 
disease categories who did not already have these CPT codes documented. We 
excluded from analysis participants for whom CPT code collection was incomplete due 
to provider nonresponse to code collection requests. We also excluded individual CPT 
codes deemed unrelated to LD, per consultation with an infectious disease physician, 
that were collected coincidentally from providers (Table A.4). 
Table A.2 Characteristics of the subset of participants with complete out-of-









Disease category Confirmed localized 273 44.5 54.4 
 Confirmed disseminated 154 25.1 20.2 
 Probable  186 30.3 25.4 
     
Age group (years) < 18 173 28.2 27.7 
18 – 45 96 15.7 15.7 
46 – 65 228 37.2 37 
> 65 116 18.9 19.5 
     
Gender Female 262 42.7 43.0 
Male 351 57.3 57.0 
     
Race Non-white 45 7.3 7.1 
 White 568 92.7 92.9 
     
State CT 128 20.9 19.3 
MD 203 33.1 33.6 
MN 191 31.2 31.1 
NY 91 14.8 15.9 
     
Income1 ≤ $60,000 160 28.7 28.4 
> $60,000 398 71.3 71.6 
     
Insurance Private 438 28.5 28.5 
Other 175 71.5 71.5 
     
Median clinician 
visits (range) 
 2 (1 - 33) NA NA 
     
Median surveys 
(range) 
 3 (1 - 12) NA NA 
1 Participants were not required to provide information on income; n = 558 
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Equation A.1 Multivariable linear regression model equation 
We used a multivariable linear regression model to estimate the relative impact of our 
independent variables of interest on the total societal cost of Lyme disease (LD) per 
patient. As is typical for healthcare cost data, the distribution of total cost was highly 
skewed, resulting in heteroskedasticity of the residuals in the model [115]. Therefore, 
we transformed total cost per patient using natural logarithms and conducted sampling-
weighted least squares regression. The basic equation is as follows:  
log(Yi) = β0 + βTXi + ϵi 
where Yi, is the dependent variable, the total societal cost of LD for patient i; Xi is a 
vector of covariates; and ϵi is a mean-zero random error. The equation is written as 
follows for our specific vector of covariates (i.e., independent variables of interest and 
potential confounders): 
log(Yi) = β0 + β1Disease categoryi + β2Age groupi + β3Genderi + β4Statei +  
β5Insurance statusi + β6Incomei + β7Study yeari + ϵi 
 
Baseline costs come from the intercept term, β0, which represents a patient with 
confirmed localized Lyme disease, female, aged < 18 years, with residence in CT, 
without private insurance, with income < $60,000, and study year of 2014. Resulting 
beta coefficients were back transformed by exponentiation, interpreted as the 
multiplicative difference in the geometric mean of the total cost of Lyme disease for a 1-
unit difference in the independent variable of interest after adjusting for confounders. We 
calculated the percent difference in cost from baseline for each level of each 
independent variable, excluding reference (i.e., baseline) levels (Percent difference = 
(Exp(coefficient) – 1) * 100). These additional costs were added or subtracted to the 
baseline costs for each independent variable of interest (see Chapter 3, Table 3.5 and 
Table A.7 for results).  
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Table A.3 Mean and median out-of-pocket Lyme disease costs per patient, by disease and cost category, 2016 
USD* 
 Confirmed localized disease  Confirmed disseminated disease  Probable disease 














0 (0, 0) 540 (368, 712) 0 (0, 0) 727 (359, 1095) 0 (0, 0) 627 (429, 824) 
Medical bills 42 (31, 52) 314 (201, 426) 83 (61, 145) 628 (408, 848) 83 (62, 99) 389 (264, 514) 
Prescription 
medicine 
16 (11, 21) 56 (32, 80) 21 (17, 21) 79 (54, 105) 19 (16, 21) 44 (34, 54) 
Over-the-counter 
medicine 
0 (0, 4) 20 (13, 27) 10 (7, 10) 53 (28, 78) 5 (2, 8) 47 (21, 72) 
Transportation 11 (10, 12) 34 (16, 52) 20 (17, 23) 55 (37, 74) 18 (14, 20) 49 (30, 69) 
Home 
maintenance 
0 (0, 0) 31 (7, 55) 0 (0, 0) 58 (12, 103) 0 (0, 0) 50 (4, 97) 
Other 0 (0, 0) 40 (23, 58) 0 (0, 0) 78 (37, 118) 0 (0, 0) 51 (27, 75) 
Care for 
self/dependents 
0 (0, 0) 35 (0, 91) 0 (0, 0) 14 (0, 28) 0 (0, 0) 20 (0, 42) 
* This table is a complement to the information displayed in Chapter 3, Figure 3.2. All calculations use the sample-weighted data. 
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Table A.4 List of CPT codes removed from analyses, code description, frequency, 
mean cost per code (n = 30)* 
CPT CODE CODE DESCRIPTION N MEAN COST 
(2016 USD) 
11406 Removal of growth (4.0 centimeters) of the trunk, arms, or legs 1 1152 
11606 Removal of malignant growth (over 4.0 centimeters) of the trunk, arms, or legs 1 1240 
36475 Destruction of insufficient vein of arm or leg, accessed through the skin 1 3021 
37609 Tying or biopsy of temporal artery (side of skull) 1 1844 
42821 Removal of tonsils and adenoid glands patient age 12 or over 1 1946 
42830 Removal of adenoids patient younger than age 12 1 1854 
43238 Ultrasound guided needle aspiration or biopsies of esophagus using an endoscope 1 1664 
45378 Diagnostic examination of large bowel using an endoscope 4 752 
45380 Biopsy of large bowel using an endoscope 1 1131 
45385 Removal of polyps or growths of large bowel using an endoscope 2 2911 
47562 Removal of gallbladder using an endoscope 1 4062 
55700 Biopsy of prostate gland 1 679 
59510 Cesarean delivery with pre- and post-delivery care 1 2893 
62311 Injections of substances into lower or sacral spine 3 565 
64490 Injections of upper or middle spine facet joint using imaging guidance 1 788 
64491 Injections of upper or middle spine facet joint using imaging guidance 1 531 
64492 Injections of upper or middle spine facet joint using imaging guidance 1 502 
64635 Destruction of lower or sacral spinal facet joint nerves using imaging guidance 1 1155 
64636 Destruction of lower or sacral spinal facet joint nerves with imaging guidance 1 801 
66984 Removal of cataract with insertion of lens 3 2415 
69436 Incision of eardrum with insertion of eardrum tube under general anesthesia 1 1802 
78582 Lung ventilation & perfusion imaging 1 598 
92928 Catheter insertion of stents in major coronary artery or branch, accessed through the 
skin 
1 3530 
95810 Sleep monitoring of patient (6 years or older) in sleep lab 1 1535 
C1725 Catheter, transluminal angioplasty, non-laser (may include guidance, 
infusion/perfusion capability) 
2 2182 
C1874 Stent, coated/covered, with delivery system 1 5411 
C9600 Percutaneous transcatheter placement of drug eluting intracoronary stent(s), with 
coronary angioplasty when performed; single major coronary artery or branch 
1 12616 
G0202 Screening mammography digital 14 490 
G0206 Diagnostic mammography digital 3 523 
J0133 Injection, acyclovir, 5 mg 1 824 
 
* An infectious disease physician with subject matter expertise in Lyme disease deemed these CPT codes to be unrelated to Lyme 
disease; 54 instances with these 30 codes recorded were deleted from the dataset prior to all analyses. 
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Table A.5 Twenty-five most frequently reported CPT codes, code description, and summary statistics 










99213 Established office visit 970 0.1 100.55, 85.14 75.04, 74.70 
99214 Established patient office or other outpatient, visit typically 25 minutes 707 0.07 144.43,120.56 112.68,115.18 
36415 Routine venipuncture 579 0.06 8.40, 3.89 3.00, 3.00 
Q9967 LOCM 300-399mg/ml iodine,1ml 344 0.04 336.87,165.17 152.19,165.17 
86617 Confirmation test for antibody to Borrelia burgdorferi (Lyme disease 
bacteria) 
308 0.03 64.58, 32.82 28.49, 28.49 
85025 Complete blood cell count (red cells, white blood cell, platelets), 
automated test 
287 0.03 26.57, 18.03 14.30, 14.30 
86618 Analysis for antibody Borrelia burgdorferi (Lyme disease bacteria) 273 0.03 42.44, 33.62 31.32, 31.32 
J3490 Unclassified drugs 180 0.02 489.57, 28.90 37.95, 28.90 
97110 Therapeutic exercises 166 0.02 64.88, 49.72 33.17, 32.36 
J1642 Injection, heparin sodium, (heparin lock flush), per 10 units 130 0.01 248.86, 24.21 24.21, 24.21 
80053 Blood test, comprehensive group of blood chemicals 105 0.01 40.06, 14.87 19.43, 19.43 
97112 Neuromuscular reeducation 102 0.01 44.74, 25.22 34.03, 33.71 
86140 Measurement C-reactive protein for detection of infection or 
inflammation 
96 0.01 21.47, 9.49 9.52, 9.52 
98940 Chiropractic manipulative treatment, 1-2 spinal regions 88 0.01 38.20, 28.00 29.52, 29.43 
80048 Blood test, basic group of blood chemicals 87 0.01 33.53, 18.90 15.55, 15.55 
J0696 Injection, ceftriaxone sodium, per 250 mg 85 0.01 165.44, 32.76 44.70, 32.76 
A9585 Injection, gadobutrol, 0.1 ml 83 0.01 228.98, 90.00 90.01, 90.00 
99212 Established patient office or other outpatient visit, typically 10 minutes 82 0.01 68.39, 51.74 45.35, 45.11 
90471 Administration of 1 vaccine 78 0.01 26.87, 24.47 26.56, 25.52 
99203 New patient office or other outpatient visit, typically 30 minutes 77 0.01 138.31,109.00 112.28,116.07 
85652 Red blood cell sedimentation rate, to detect inflammation 76 0.01 10.53, 4.73 4.97, 4.97 
93000 Routine EKG using at least 12 leads including interpretation and report 75 0.01 47.41, 38.79 17.95, 18.34 
87880 Strep test (Streptococcus, group A) 70 0.01 20.26, 17.31 22.05, 22.05 
99284 Emergency department visit, problem of high severity 70 0.01 532.25,411.12 119.94,120.87 
85027 Complete blood cell count (red cells, white blood cell, platelets), 
automated test 










Mean (2016 USD) 
 
Median (2016 USD) 
 
Disease category Confirmed localized 273 1307 493 
 Confirmed disseminated 154 3251 1081 
 Probable  186 2620 940 
     
Age group (years) < 18 173 1550 503 
18 – 45 96 2100 960 
46 – 65 228 2421 1136 
> 65 116 1926 521 
     
Gender Female 262 1417 646 
Male 351 2497 741 
     
Race Non-white 45 2188 774 
 White 568 2021 685 
     
State CT 128 3307 621 
MD 203 1493 604 
MN 191 2112 1124 
NY 91 1470 434 
     
Income1 ≤ $60,000 160 2159 685 
> $60,000 398 2088 696 
     
Insurance Private 438 2295 807 
Other 175 1376 578 























(Intercept)4 5.72 0.20 305.08 NA NA 
206.28 – 
451.20 < 0.001 
Confirmed 
disseminated 0.79 0.11 2.20 120 366.58 
188.12 – 
545.04 < 0.001 
Probable 0.47 0.10 1.59 59 181.13 70.84 – 291.42 < 0.001 
18 – 45 years 0.67 0.15 1.96 96 292.99 107.11 – 478.88 < 0.001 
46 – 65 years  0.73 0.11 2.08 108 330.79 175.08 – 486.50 < 0.001 
> 65 years 0.24 0.17 1.27 27 83.65 -27.51 – 194.81 0.15 
Male 0.11 0.09 1.11 11 34.56 -25.67 – 94.8 0.24 
MD 0.00 0.13 1.00 0 -0.01 -75.98 – 75.97 1.00 
MN 0.56 0.13 1.75 75 229.44 113.85 – 345.03 < 0.001 
NY -0.06 0.17 0.94 -6 -18.52 -118.96 – 81.91 0.72 
Privately insured 0.24 0.15 1.27 27 82.53 -23.22 – 188.28 0.11 
> $60,000 
income -0.06 0.12 0.94 -6 -18.52 
-90.11 – 
53.08 0.61 
Study year 2015 -0.07 0.10 0.93 -7 -21.35 306.05 – 427.11 0.48 
Study year 2016 0.50 0.50 1.65 65 197.52 -306.37 – 668.64 0.32 
1The model included independent variables of interest, i.e., disease category, age group, gender, and state, while controlling for insurance 
status, income, and study year. Reference levels are not shown but are described in Table 3.5 of Chapter 3. Adjusted R2 = 0.19.  
2 Beta coefficients were back transformed by exponentiation, interpreted as the multiplicative difference in the geometric mean of the total 
cost of Lyme disease for a 1-unit difference in the independent variable of interest after adjusting for confounders. 
3Percent difference = (Exp(coefficient) – 1) * 100; this represents the percent change in cost from baseline for each level of each variable, 
excluding reference (i.e., baseline) levels. 
4Baseline cost (i.e., e β0) represents a patient with confirmed localized Lyme disease, female, aged < 18 years, with residence in CT, without 






Section A.2 Description of calculations for extrapolation of total cost per patient 
to annual, aggregate total societal cost in the U.S. 
In 2016, 36,429 cases of LD were reported via surveillance. Previous research 
has demonstrated that surveillance cases numbers are likely 8 – 12 fold underreported 
[6, 7]. If we assume a 10-fold increase in reported case numbers, we estimate that in 
2016 there were approximately 364,290 cases in the U.S. The table below shows total 
cases broken down by confirmed localized, confirmed disseminated, and probable 
disease per the proportions found in surveillance data. To estimate the total aggregate 
cost of LD to U.S. society, case numbers by disease category are multiplied by the 
mean total cost per patient estimated from this study for an aggregate cost per disease 
category. When summed, the total cost of LD in the U.S. annually is approximately 
$734,878,574 (2016 USD). In 2020 USD, this cost is $788,615,003 using the Consumer 
Price Index (CPI) for all consumers and $818,510,585 when using the CPI for medical 
care [170]. 
Table A.8 Inputs for extrapolation of total cost per patient to aggregate total 












Confirmed localized 0.55 199315 1,307 257,108,596 
Confirmed 
disseminated 
0.21 76744 3,251 248,704,426 
Probable 0.24 88231 2,620 229,065,552 
  TOTAL (2016 USD) 734,878,574 
  TOTAL (2020 USD) * 788,615,003 
  TOTAL (2020 USD, medical CPI)** 818,510,585 
*Converted to 2020 USD using Consumer Price Index, “All items in U.S. city average, all urban consumers, not seasonally adjusted” 
(CPI-U, Series ID: CUUR0000SA0). 2016 annual average CPI and 2020 first half of year average CPI used. Data extracted from 
https://data.bls.gov/pdq/SurveyOutputServlet on 9/30/2020. 
**Converted to 2020 USD using Consumer Price Index, “Medical care in U.S. city average, all urban consumers, not seasonally 
adjusted” (CPI-U Medical care, Series ID: CUUR0000SAM). 2016 annual average CPI and 2020 first half of year average CPI used. 






APPENDIX B: SUPPLEMENTAL MATERIAL FOR CHAPTER 4, EVALUATING PUBLIC 
ACCEPTABILITY OF A POTENTIAL LYME DISEASE VACCINE USING A 
POPULATION-BASED, CROSS-SECTIONAL SURVEY IN HIGH INCIDENCE AREAS 




Table B.1 Select vaccine acceptability survey questions and response 
options*  
Question Response options 
If a Lyme disease vaccine were available, would you get 
vaccinated? Yes No 
Don't know/not sure 
How concerned are you about the safety of a Lyme disease 
vaccine? Not at all concerned Somewhat concerned 
Very concerned 
Don't know/not sure 
How much would the cost of a Lyme disease vaccine affect 
your decision to get vaccinated? Not at all Some 
A lot 
Don't know/not sure 
How much would a positive recommendation from your 
doctor affect your decision to get vaccinated? Not at all Some 
A lot 
Don't know/not sure 
Has anyone in your household ever been diagnosed with LD 
by a health care professional? Yes  No 
Not sure 
How concerned are you about getting LD in the future? Not at all concerned 
Somewhat concerned 
Very concerned 
Don't know/not sure 
In the months April-October, do you spend time in or near 
places where ticks could get on you (for example, wooded or 





Yes, less than once a month 
No 
Don't know/not sure 
Which of the following measures do you take to prevent ticks 
from getting on you? (Check all that apply) Apply insect repellent Check for ticks 
Use special clothing 
Use sprays in your yard 
Other measures 
None of these 
How confident are you that these measures can prevent LD? Very confident 
Somewhat confident 
Not at all confident 
Don't know/not sure 
Where do you most often get information about Lyme 
disease? (choose one) 
Doctor, nurse, or other medical professional 
Naturopath or chiropractor 
Friends or family members 





Social media sites 
Other 
How confident are you that recommended vaccines benefit 
people?  Very confident Somewhat confident 
Not at all confident 
Don't know/not sure 
Where do you usually get vaccines? (choose one) Doctor's office, clinic, or hospital  






I do not get vaccines 
* Questions for the parent survey were identical, but phrased with the child as vaccinee (e.g., “If a LD 

































category*             
Gender*             
State X    X        
Race      X       




X X   X  X X X X X X 
HCP influence 
on LD 
vaccination X X   X   X X X X X 
LD vaccine 






Table B.3 Observed and weighted respondent characteristics, N = 3206 
Characteristic  N Unweighted % 
Weighted % 
(95% CI) * 
Demographics     
Gender**     
Female  1878 59 54 
Male  1328 41 46 
Age category** (years)     
< 18  246 8 15 
18-44  772 24 33 
45-64  1225 38 34 
65+  963 30 17 
State     
Connecticut  679 21 20 
Maryland  808 25 27 
Minnesota  998 31 20 
New York  721 23 33 
Race     
White  2852 90 85 (84, 86) 
Non-white  322 10 15 (14, 16) 
Education     
Some college or less  1248 39 35 (33, 36) 
Bachelor’s degree or higher  1941 61 65 (64, 67) 
Metropolitan status     
Large central metropolitan area  674 21 28 
Other  2532 79 72 
     
LD history, attitudes, and practices     
Past LD diagnosis in household     
Yes  640 20 18 (17, 19) 
No  2563 80 82 (81, 83) 
Concern about future LD diagnosis     
Yes  2813 88 86 (85, 86) 
No  391 12 14 (14, 15) 
Spend time in tick habitat     
At least weekly  2376 74 71 (70, 73) 
Monthly or less  828 26 29 (27, 30) 
Currently use LD prevention 
measures     
Yes  2948 92 92 (91, 93) 
No  258 8  8 (7, 9) 
Confidence in LD prevention 




Yes  2041 70 70 (68, 71) 
No  896 30 30 (29, 32) 
Confidence in general vaccines     
Yes  3022 94 94 (93, 95) 
No  182 6 6 (5, 7) 
LD vaccine attitudes     
Willing to receive LD vaccine     
Yes  2098 65 64 (62, 65) 
No  190 6 7 (6, 8) 
Don’t know  918 29 30 (28, 31) 
LD vaccine safety concerns     
Yes  2257 70 71 (70, 72) 
No  948 30 29 (28, 30) 
HCP influence on LD vaccination     
Yes  2858 89 89 (88, 89) 
No  348 11 11 (11, 12) 
LD vaccine cost concerns     
Yes  2036 64 63 (62, 65) 
No  1168 36 37 (35, 38) 
* County distributions of gender and age were used for post-stratification; as such, these point estimates are fixed at 
the population values and have no associated interval estimate. Because state and metropolitan status are based on 
county population totals, these point estimates are also fixed. 
**Gender and age categories represent the potential vaccinee, i.e., adult respondents and the children for whom 
parents responded. 
 
Section B.1 Heckman-type selection models 
We evaluated non-random missingness in our outcome variable, willingness to receive 
a LD vaccine, in relation to non-response (i.e., selection bias) using Heckman-type 
selection models, also called generalized Tobit models [135-137]. Heckman-type 
selection models correct for selection bias when nonparticipation is determined both by 
observed and by unobserved factors. Performance depends on the availability of 
selection variables that determine survey participation but do not independently affect 
the outcome of interest. Heckman models use two steps to first model the selection 
process using one or more independent selection variables and then model the 
outcome equation (i.e., the regression equation for the outcome of interest). The key 
feature of Heckman-type selection models is that a correlation between the unobserved 
error terms in the selection equation and outcome equation is estimated (r). The 
coefficient of the inverse Mill’s ratio represents the covariance between the error terms, 
and has an associated p-value. These results of the two-step process indicate whether 
selection bias is present and, if so, a correction factor can be applied to results. 
We chose two selection variables, presence of children in the household and household 
member count, under the assumption that these variables were predictive of 




vaccine. For example, those with children in the household and/or higher numbers of 
household members may not have time to participate in a voluntary survey. All variables 
in the selection equation must be available for all sampled individuals, regardless of 
participation. Independent variables for all sampled households were purchased from 
the marketing firm from which addresses were purchased. The selection equation 
included the following: 
Selection ~ endemicity + property type + household income + presence of 
children in household + household member count                
The outcome equation includes the independent variables from the selection equation, 
excluding the selection variables. The outcome equation included the following: 
Vaccine decision ~ endemicity + property type + household income 
Table B.4 shows the results of the Heckman-type selection models using the two-step 
process. Of note, r = 0.7 and the coefficient of the inverse Mill’s ratio is 0.4305 (p = 
0.5307), meaning that the data are consistent with no selection bias (i.e., the null 
hypothesis that the errors are uncorrelated cannot be rejected).  
These results are limited by the fact that only variables available for the entire sample 
could be used in the evaluation. Further, the accuracy of these variables typically used 
for marketing research are questionable, plus some records were missing observations 
for these variables. Lastly, our assumption that the selection variables, presence of 
children in household and household member count, are unrelated to the willingness to 
vaccinate outcome is somewhat tenuous. For example, because children are one of the 
groups at highest risk for LD, parents with children in the household may be more likely 
to participate in a survey about a LD vaccine and also express willingness to vaccinate 
their children. 
 
Table B.4 Results of Heckman-type selection 
models 
Dependent variable: 
Willingness to receive LD vaccine (0= No/DK; 1 = Yes) 
  Terms                                  Coefficient 
(95% CI) 
 
Endemicity:  -0.0223 
Non-endemic (-0.1285, 0.0840) 
Property type:  0.0690 
Single family dwelling unit (-0.0825, 0.2206) 
Household income:  0.0709 





 (-2.4066, 1.9078) 
Observations 34,667 
R2 0.0006 
Adjusted R2 -0.0009 
Log Likelihood  
Akaike Inf. Crit.  
rho 0.6958 
Inverse Mills Ratio 0.4305 (0.5307) 
1The selection equation for the Heckman selection model 
used presence of children and household member count 







Table B.5 Comparison of adjusted odds ratios (aORs) from multinomial logistic regression (MLR) and 
aORs and adjusted prevalence ratios (aPRs) from standard logistic regression (SLR) 
  LD vaccination responses (ref. = Yes) 
  No  Don’t Know 
Variable  MLR aOR  
(95% CI) 
SLR aOR  
(95% CI) 
SLR aPR  
(95% CI) 
 MLR aOR  
(95% CI) 
SLR aOR  
(95% CI) 
SLR aPR  
(95% CI) 
         
Vaccinee age category*  
(ref. = 65 + years) 
    
 
   
 <18  1.19 (0.38, 3.68) 1.11 (0.86, 1.42) 1.10 (0.88, 1.37)  1.60 (1.06, 2.42) 1.60 (1.35, 1.91) 1.37 (1.22, 1.53) 
 18 – 44  1.23 (0.69, 2.19) 1.16 (0.91, 1.48) 1.14 (0.92, 1.43)  0.91 (0.66, 1.26) 0.93 (0.81, 1.08) 0.95 (0.86, 1.06) 
 45 – 64  1.59 (0.88, 2.85) 1.45 (1.11, 1.90) 1.40 (1.10, 1.78)  1.40 (1.07, 1.85) 1.37 (1.19, 1.57) 1.24 (1.12, 1.36) 
Gender*  
(ref. = Male) 
        
 Female   1.55 (0.90, 2.68) 1.48 (1.21, 1.82) 1.43 (1.19, 1.71)  1.00 (0.77, 1.31) 1.00 (0.90, 1.12) 1.00 (0.93, 1.08) 
State1  
(ref. = Connecticut) 
        
 Maryland  1.16 (0.61, 2.19) 0.99 (0.71, 1.39) 0.99 (0.73, 1.34)  1.42 (1.01, 1.99) 1.35 (1.13, 1.62) 1.23 (1.09, 1.39) 
 Minnesota  1.51 (0.76, 3.00) 1.39 (1.03, 1.87) 1.34 (1.03, 1.75)  1.19 (0.82, 1.73) 1.17 (0.98, 1.4) 1.12 (0.99, 1.27) 
 New York   1.41 (0.80, 2.48) 1.48 (1.08, 2.03) 1.41 (1.07, 1.87)  1.52 (1.05, 2.19) 1.47 (1.25, 1.73) 1.3 (1.16, 1.45) 
Race2  
(ref. = White) 
        
 Non-white   2.29 (1.21, 4.32) 2.2 (1.70, 2.84) 1.98 (1.60, 2.46)  1.54 (1.10, 2.17) 1.59 (1.35, 1.88) 1.35 (1.22, 1.49) 
Education3 
(ref. =  ≥ Bachelor’s degree) 
        
 < Bachelor's degree  2.21 (1.28, 3.83) 1.91 (1.55, 2.37) 1.75 (1.45, 2.12)  1.47 (1.13, 1.91) 1.45 (1.30, 1.62) 1.28 (1.19, 1.37) 
LD vaccine safety concerns4  
(ref. = No) 
        
 Yes  2.62 (1.49, 4.60) 3.02 (2.26, 4.03) 1.99 (1.61, 2.46)  1.99 (1.42, 2.78) 1.99 (1.74, 2.28) 1.48 (1.36, 1.60) 
HCP influence on LD vaccination5 
 (ref. = Yes) 
        
 No   5.21 (2.72, 
10.00) 
5.12 (3.92, 6.70) 2.77 (2.29, 3.35)  1.42 (0.94, 2.15) 1.37 (1.09, 1.71) 1.22 (1.10, 1.36) 
LD vaccine cost concerns6  
(ref. = No) 
        





Figure B.1. Respondents’ primary source for LD information, by potential LD vaccination decision, weighted % 
and 95% confidence intervals* 







Figure B.2. Respondents’ primary location for receiving vaccination, by potential LD vaccination decision, 
weighted % and 95% confidence intervals*  






APPENDIX C: SUPPLEMENTAL MATERIAL FOR CHAPTER 5, COST-BENEFIT ANALYSIS OF VACCINATING A 




Table C.1 Total cost of Lyme disease per patient, by disease category (from Aim 1, Chapter 3) 















All  613 771 2,272 6,809 227 380 1,779 4,696 60 – 137,228 
Confirmed 
localized  
273 551 1,461 3,978 173 280 1,487 2,994 60 – 20,480 
Confirmed 
disseminated  
154 1,208 3,634 2,3371 332 596 2,680 6,973 241 – 137,228 
Probable  186 1,051 2,929 17,363 353 580 1,957 5,613 145 – 117,928 
* Total cost includes patient out-of-pocket nonmedical costs, productivity losses, and direct medical costs. The estimates for the overall population 





Table C.2 Model parameter values for optimistic and pessimistic scenarios 
 Optimistic scenario value Pessimistic scenario value 
Probability variables   
Vaccination   
 Efficacy 0.99 0.7 
 Uptake 0.94 0.64 
Lyme disease   
Incidence, endemic states 0.08 0.001 
Confirmed, localized disease 0.55 0.55 
Confirmed, disseminated disease 0.21 0.21 
Probable disease 0.24 0.24 
Sequelae    
Confirmed, localized disease 0.07 0.00  
Confirmed, disseminated disease 0.28 0.18 
Probable disease 0.18 0.10 
Suspected Lyme disease (i.e., tested, non-Lyme disease)   
Incidence, suspected LD 0.063 0.057 
Incidence, suspected LD if vaccinated 0.011 0.013 
Costs (USD 2020)   
Vaccination   
Vaccination series and administration 28 684   
Lyme disease   
Confirmed, localized disease 2,994 173 
Confirmed, disseminated disease 6,973 332 
Probable disease 5,613 353 
Sequelae   
Sequelae 23,322 7,728 
Suspected Lyme disease (i.e., tested, non-Lyme disease)   







Figure C.1 Impact of select model parameters on the net cost per vaccinee resulting from one-way sensitivity 
analyses using minimum and maximum cost per Lyme disease category* 
*See Appendix Table C.1 for the range of costs for confirmed localized, confirmed disseminated, and probable disease. Probabilities for suspect LD, cost of suspect LD, and 
probabilities for sequelae had a negligible impact on the net cost per vaccinee and were not included in the plot.  







Figure C.2 Impact of vaccine price and Lyme disease incidence on the net cost 
per vaccinee 
